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STUDIES INVESTIGATING PERIPHERAL BLOOD DERIVED CELLS THAT EXPRESS THE 
HIGH AFFINITY RECEPTOR FOR IMMUNOGLOBULIN E (FcRI) IN ALLERGIC DISORDERS
By Bhupinder Singh Sihra
It is just forty years since the identification of immunoglobulin E (IgE) as the reagin responsible for 
allergen induced immediate hypersensitivity reactions. IgE exerts its biological actions through the 
binding of its Fc fragment to specific Fc receptors on effector cells. There are two predominant Fc 
receptors for IgE – FcRI, which has a very high affinity for IgE and FcRII, which shows less avid 
binding. For much of the first two decades after the identification of IgE, it was thought that FcRI 
expression was limited to mast cells and basophils and that IgE binding to other cell types such as B-
lymphocytes and antigen presenting cells (APCs) was mainly due to FcRII . However with major 
advances in characterisation and functional knowledge of FcRI, particularly in the last fifteen years, it 
has become apparent that FcRI can be expressed on several more cell types that may be involved in 
initiation and maintenance of allergic inflammation – including APCs (monocytes and dendritic cells) 
and possibly eosinophils.
  The research described in the four papers forming this thesis was completed during this period and 
evaluated FcRI expression on different cell types, their potential roles in allergen induced 
inflammatory responses and whether successful therapeutic strategies for allergic disorders may 
involve actions on FcRI+ cells. The relative expression of FcRI on peripheral blood basophils, 
monocytes and eosinophils from atopic and non-atopic subjects and any relationship with serum IgE 
concentrations was assessed in the first paper. The second study examined a potentially important role 
for basophils as a cellular source of rapidly releasable IL-4 which may help initiate allergen induced 
TH2 responses. The next study investigated the possible effects on allergen induced early and late 
asthmatic responses of the immunosuppressive drug cyclosporin A which had been shown both to 
inhibit mast cell and basophil degranulation and cytokine secretion (particularly by CD4+ T-cells). The 
final study evaluated FcRI expression on these cell types as well humoral factors (e.g. seasonal 
changes in allergen specific IgG and IgE) in subjects who, after 3 to 4 years of grass pollen 
immunotherapy, had continued on either active or placebo immunotherapy for a further 3 years.
  A historical perspective explaining some of the reasons the studies were done is provided in the 
introductory chapter whilst the discussion chapter at the end reviews how many of the findings of the 
study have evolved in subsequent years right up to the present day and finishes off  with a brief 
synopsis of how rapidly increasing knowledge of the regulatory functions of dendritic cells (expressing
FcRI and often monocyte derived) has resulted in better understanding of the mechanisms of allergen 
specific immunotherapy and is leading to more effective treatment modalities.iii
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FcRII  low affinity Fc receptor for immunoglobulin E
Ig immunoglobulin
IgE immunoglobulin E
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IL interleukin
IT immunotherapy
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MIRR multichain immune recognition receptor
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PBMC peripheral blood mononuclear cell
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pDC plasmacytoid dendritic cell
PL phospholipase
SCIT subcutaneous immunotherapy (allergen specific)
SLIT sublingual immunotherapy (allergen specific)
TH T helper cell subset (e.g. TH1 or TH2)
Treg Regulatory T lymphocyte
TLR Toll like receptor1
Chapter 1
Introduction:
The High Affinity Fc Receptor for Immunoglobulin E in Allergic 
Diseases – A Brief Review
“Whereof what's past is prologue, what to come
in yours and my discharge”
                                           The Tempest, Act II, Scene 1
1.1 Format And Context Of This Thesis 
This main body of this thesis comprises of four papers all written in the late 1990s
(Sihra et al. 1997a;Sihra et al. 1997b;Kon, Sihra et al. 1998; Sihra et al. 2000). The 
studies described in these papers all investigated either the expression of FcRI, the 
high affinity Fc receptor for immunoglobulin E (IgE), on peripheral blood leucocytes 
or aspects of the roles of blood-derived FcRI bearing cells play in allergic 
inflammation. One aim of this dissertation is to provide a historical perspective to
these four studies by describing the nature and chronology of research investigating
immunoglobulin E and its high affinity Fc receptor  from the discovery of IgE right 
up to the end of the last decade, when the research described in these four papers was 
undertaken. This will be the main objective of this introductory chapter. A further aim 
of the thesis is to provide a review of progress in the areas of research covered by 
each these four studies in the period since they were concluded and this will be done 
in the discussion in Chapter 6.
1.2 Immunoglobulin E (IgE)
1.2.1 Brief history 
The story of the identification of IgE goes back to the early 1920s when Carl 
Prausnitz and Heinz Küstner first demonstrated the existence of a factor in the serum 
of an allergic patient that could passively transfer immediate skin reactivity to a non-2
allergic patient (the PK test) (Prausnitz & Küstner 1921). Coca and Cooke in 1923 
reported that this serum factor (or ‘body’) was heat labile and termed it ‘reagin’ 
(advising avoidance of the term antibody as at that stage there was “no evidence that 
these bodies appeared as the result of immunological stimulation”) (Coca & Cooke 
1923).
Despite great efforts, further progress towards identifying and characterising this 
reagin was frustratingly slow for the next four decades until, as has often been the 
case in medical science, two groups working independently made almost 
simultaneous breakthroughs. In 1967 Teruko and Kimishige Ishizaka (based in 
Denver) managed to characterise this reagin as a new class of immunoglobulin which 
they provisionally called the ‘E-globulin’ (Ishizaka & Ishizaka 1967). At almost the 
same time Hans Bennich and Gunnar Johansson in Uppsala, Sweden detected an 
atypical myeloma protein (provisionally called IgND) which demonstrated many of 
the physicochemical properties of the reagin (Johansson & Bennich 1967). They 
further demonstrated that this IgND was present in low concentrations in serum of 
healthy and allergic individuals but serum concentrations were significantly higher in 
allergic asthmatics when compared to normal controls (Johansson 1967). In addition 
it was demonstrated that both whole IgND and its Fc fragment could block the PK 
reaction (passive transfer of skin reactivity) in human subjects (Stanworth et al. 
1967;Stanworth et al. 1968).
Investigators quickly established that E-globulin and IgND shared antigenic 
properties. At a World Health Organisation workshop in 1968 it was finally agreed 
that there was enough data available that both E-globulin and IgND were the same 
protein and that this new class of immunoglobulin (termed Immunoglobulin E or IgE) 
was indeed the reagin first described in the 1920s (Bennich et al. 1968).
It was the discovery of immunoglobulin E that really ushered in the modern era of the 
science of allergy that, together with major advances in cell and molecular 
immunology as well as genetic techniques in the intervening four decades, has led to 
greatly increased understanding of allergic diseases and allergic inflammation. 3
1.2.2 IgE structure
Immunoglobulin E is the least abundant of the 5 immunoglobulin subclasses in serum 
with concentrations typically around 10
-5 times those of immunoglobulin G, IgG. 
Like other immunoglobulins, an IgE molecule has 2 identical heavy ( class) and 2 
identical light ( or ) chains and can be cleaved proteolytically into an antigen 
binding fragment (Fab), composed of one constant and one variable domain of each 
heavy and the light chain, and a crystallisable fragment (Fc) which contains the cell 
receptor binding site (Bennich et al. 1968). In contrast to IgG, which has 2 constant 
domains in the Fc region, the Fc portion of IgE has an extra constant domain (C2)
(figure 1) (McDonnell et al. 2001). As will be discussed later this extra domain has 
recently been shown to have important functional implications particularly related to 
stabilising the binding of IgE to its high affinity receptor FcRI (McDonnell et al.
2001;Wan et al. 2002).
            
Figure 1:   Representative illustrations of the polypeptide and domain structures of the IgE 
molecule (from B.J. Sutton and H.J. Gould, Allergy and Allergic Diseases Ed. A. B. Kay)
Although high resolution x-ray diffraction studies of the crystal structure of 
immunoglobulin E would only be available at the start of the current decade, 
fluorescence resonance energy transfer analyses published in the early 1990s revealed 
that the IgE molecule is not the simple Y-shaped structure depicted above, but is in 
that the C2 region acts as a hinge with the two C3 domains being twisted into a 
fact a compact, tightly bent structure (Zheng et al. 1991). Further studies suggested 4
convex loop (one C3 on the outside and one on the inside) (Beavil et al. 1995). 
Further details of the crystal structure of IgE and its interaction with the FcRI chain 
are provided in section 1.5.
1.3 Immunoglobulin E And Its Fc Receptors
Although the role of immunoglobulin E (IgE) in the initiation and maintenance of 
allergic inflammation is well established today, it is sometimes forgotten that it is 
only in the last decade and a half that there have been a number of major, and 
astonishingly rapid, advances in our understanding of many of the underlying 
mechanisms involved. The four core papers of this thesis all describe work done 
during this period and reflect these evolving changes in our understanding of these 
processes.
Previously it was known that IgE binds to the surface membrane of tissue mast cells 
and circulating basophils with a much higher affinity than other immunoglobulins 
bind to their particular receptors (FcR) on other immune effector cells (Malveaux et 
al. 1978;Coleman & Godfrey 1981;Pruzansky & Patterson 1986) and that IgE 
mediated exocytosis of mediators (such as histamine) from these two cell types was 
important in immediate hypersensitivity reactions (Ishizaka et al. 1973;Ishizaka & 
Ishizaka 1978). It also appeared that IgE could also bind to other cell types (including 
B-lymphocytes as well antigen presenting cells like monocytes) but the binding to 
these cells was less avid than to mast cells and basophils (Spiegelberg & Melewicz 
1980;Melewicz et al. 1982;Spiegelberg et al. 1983). The main focus of researchers in 
the 1980s was to try and identify the receptors involved in the high and lower affinity 
binding of IgE and also to understand the nature of the binding of IgE by its receptors
and the role this played in the effector functions of the various cells that expressed 
these receptors. 
By 1990 the high affinity Fc receptor for IgE (FcRI) on mast cells and basophils had 
been identified and it was known that it is expressed as a tetrameric structure (an , a 
 and 2  subunits) on the membrane of these specific cell types (Blank et al. 
1989;Kinet et al. 1991;Metzger 1992a). Research looking into the pivotal role played 5
by the interaction of IgE with FcRI in allergic inflammation then focused on several 
aspects almost concurrently. These included:
a. Cellular expression
Researchers began to look into the possible expression of FcRI on other cell types 
besides mast cells and basophils (including antigen presenting cells such as blood 
monocytes, blood and tissue dendritic cells (e.g. Langerhan’s cells) and, most 
intriguingly in the context of allergic inflammation, blood and tissue eosinophils). 
When it soon became apparent that high affinity Fc receptors for IgE could indeed be 
expressed on many of these cell types (Maurer et al. 1994;Maurer et al. 1996;Bieber 
1996;Gounni et al. 1994b), this led to further questions such as:
 What is the relative frequency of receptor expression on different cell types?
 Is it always necessary for all three subunits to be expressed on the surface of all 
these cells?
 Are these receptors expressed constitutively on all these cells or can they be up or 
down regulated?
 If surface expression of these receptors is inducible, what are the factors that 
affect this?
 How does the presence of FcRI on various cell types affect their roles?
Finding the answers to these questions became very much intertwined with other 
ongoing research into high affinity Fc receptors, elucidated below.
b. Structure
One fundamental question that needed answering was why IgE bound to FcRI has
such a slow dissociation phase (since this was known to be a critical rate limiting step 
resulting in the interaction between these two molecules having such a uniquely high 
binding affinity) (Wank et al. 1983;McDonnell, Calvert et al. 2001). Furthermore,
what is the basis of the observed 1:1 stoichiometry of binding between IgE and its 
high affinity receptor (i.e. an individual receptor cannot bind more than one IgE 
molecule at any given moment) (Robertson 1993;Keown et al. 1997) in contrast to Fc 
receptors for other immunoglobulin classes that often demonstrate 1:2 stoichiometry?
It was hoped that greater understanding of the basic processes involved could, in due 
course, lead to the development of new therapeutic agents which could disrupt this 6
interaction. Therefore research focused not just on determining the molecular 
structures of the three subunits that form the FcRI complex but also on trying to 
understand the nature of IgE binding to its receptor. Researchers worked particularly 
on trying to solve the three dimensional crystal structure of the -chain of the high 
affinity receptor (FcRI the chain on which the binding site for immunoglobulin 
E is situated (Blank et al. 1991;Hakimi et al. 1990)  as well as that of IgE actually 
bound to FcRI in an effort to try and determine the precise topology of this 
particular receptor-ligand interaction.
c. Function
As the diversity of cell types expressing FcRI became apparent, the obvious 
questions that arose were whether these receptors were functional and, if so, what 
role they played in different cells. Increasingly this led to an appreciation that the 
presence of high affinity receptors for IgE on various cell types could greatly expand
the rather limited and well defined roles that had been assigned to these cells in our 
understanding of inflammatory processes at that time. For instance, researchers 
began to look at the ability of FcRI on antigen presenting cells (APCs) to greatly 
facilitate IgE dependent antigen presentation to T-lymphocytes – a concept known as 
‘antigen focusing’ (Bieber 1996). It was demonstrated that the presence of allergen-
specific IgE bound to FcRI on monocytes increased their ability to present allergen 
to T-lymphocytes almost a thousand fold in vitro (Maurer et al. 1995). Even for the 
two cell types where the presence of FcRI had long been known about (mast cells 
and basophils) increasing knowledge led to the realisation that these cells may well 
have a wider role than just orchestrating immediate hypersensitivity reactions
through IgE mediated degranulation. It became apparent that these cells had the 
potential to be involved in the initiation and maintenance of chronic allergic
inflammation because of their ability to synthesise and secrete pro-inflammatory 
cytokines (e.g. interleukins- 4 and 13) in an IgE-dependent manner (Bradding 
1996;Brunner et al. 1993;Schroeder et al. 1994). Perhaps the most controversial 
observation was that eosinophils, which have been identified as major effector cells 
in chronic allergic inflammation, may have surface expression of FcRI (Gounni et 
al. 1994a). If the presence of functioning IgE receptors on eosinophils in allergic 7
diseases could indeed be confirmed, then this might provide a potent mechanism for 
rapid IgE mediated eosinophil degranulation.
d. Intracellular events
The capture of allergens by allergen specific IgE bound to the -chains of high 
affinity Fc receptors on the cell surface is only the start of a cascade of signals and 
events that may eventually lead to the variety of biological consequences mentioned
above (Beaven & Metzger 1993). A lot of research was focused on trying to elucidate 
the sequence of downstream events resulting from the cross linking of receptor bound 
IgE by a multivalent allergen. It became apparent that the - and - chains of the 
receptor complex have important roles to play in this biochemical cascade. By 1995, 
the presence of a particular 26 amino acid sequence motif, called the immunoreceptor 
tyrosine-based activation motif (ITAM) (Cambier 1995), had been demonstrated on 
the cytoplasmic C-terminal tails of both chains (figure 2). This sequence had been 
recognised as playing a central role in intracellular signal transduction by a whole 
host of immune receptors and its presence on these chains in the FcRI complex 
provided important evidence that receptor cross-linking by antigen would result in a 
number of complex but well defined intracellular signalling pathways being activated. 
This led to a great flurry of activity aimed at determining these signalling event
sequences - and indeed the understanding gained of how the FcRI orchestrates 
intracellular signalling events resulted in this receptor complex being considered as a 
paradigm of how other immune receptors function (Sandor & Lynch 1993).
1.4 Receptors For IgE
Immunoglobulin E has a relatively short half life in serum of around 2.5 days to go 
along with its low serum concentration (Waldmann et al. 1976;Manz et al. 2005) but
a large proportion of the body’s IgE is located extravascularly (Dreskin et al. 1987).
The biological actions dependent on IgE are most commonly manifested when a 
multivalent antigen cross-links antigen specific IgE bound to the surface membrane 
of certain immune effector cells.  8
Within a few years of the identification and characterisation of IgE it had become 
apparent that two cell types in particular possessed several thousand surface bound 
IgE molecules per cell – basophils and mast cells (Conroy et al. 1977;Coleman & 
Godfrey 1981). By the early 1980s it was also apparent that the receptors on these 
cells bind IgE with similarly high affinity (with an equilibrium association constant, 
Ka, of 10
9 – 10
10 M
-1) (Coleman & Godfrey 1981;Pruzansky & Patterson 1986) and
that cross-linking of surface bound IgE on both cell types was an extremely potent 
stimulator for the rapid release of vasoactive mediators (such as histamine) stored in 
intracellular granules in these cells (Conroy et al. 1977;Lowman et al. 1988). 
It was also found that IgE could also be found bound to other cells, such as 
monocytes and B-lymphocytes, but the surface density of IgE molecules on these 
cells was far less than on basophils and mast cells. Furthermore the affinity of IgE 
binding on these cell types appeared to be much lower than on basophils and mast 
cells (Ka being approximately 10
7 M
-1) (Melewicz et al. 1982;Spiegelberg & 
Melewicz 1980;Spiegelberg et al. 1983).
By the mid-1980s therefore it was clear that there were two types of Fc receptors for 
IgE with the high affinity receptor apparently confined to basophils and mast cells. 
Indeed by the end of that decade the molecular structure and cell surface 
configurations of both IgE Fc receptors had been determined (Blank et al.
1989;Kikutani et al. 1986).
In the following sections our current knowledge of the structure and function of the 
high affinity Fc receptor, FcRI, will be summarised. Whilst the low affinity Fc 
receptor also has many significant roles in IgE mediated inflammatory responses 
(including a major regulatory role in the isotype switching of B-lymphocytes towards 
IgE production), the main focus of this thesis is the high affinity Fc receptor. 
Therefore the FcRII will only be discussed relatively briefly as detailed 
consideration of its structure and functions falls beyond the scope of this dissertation.9
1.5 The High Affinity Fc Receptor For IgE
The high affinity Fc receptor is expressed on cell surfaces as a polymeric complex
consisting of a combination of three basic subunits – termed the -, - and -chains
(Metzger 1992a). It is a member of the family of multichain immune recognition 
receptors (MIRRs). This family contains several multichain receptors found on the 
surface of cells involved in antigen recognition (including the T and B cell receptor 
complexes and several types Fc receptors for immunoglobulins) (Keegan & Paul 
1992). A characteristic feature shared by members of this family is that they all form 
complexes consisting of antigen or Fc binding chains (containing extracellular 
domains belonging to the immunoglobulin superfamily) associated with one or more 
chains which usually contain the ITAM sequence on their cytoplasmic 
tails and are therefore involved in intracellular signal transduction pathways.
A. B.
Figure 2:   Schematic diagrams of the two different forms of FcRI present in cell 
membranes. A) The tetrameric form typically found on mast cells and basophils; 
B) The trimeric form on antigen presenting cells. The dark circles in the cytoplasmic domains 
of the - and - chains represent ITAM sequences. TM = transmembrane segments (from 
A.M. Scharenberg and J.P. Kinet. 1997. Int Arch Allergy Immunol; 113: 43)
The -chain of the FcRI is a transmembrane protein, with the larger part (containing 
two immunoglobulin-like domains) situated externally. The -chains form a 
disulphide-linked homodimer with the two identical chains consisting of a short 
extracellular domain, a relatively longer cytoplasmic tail and a transmembrane 10
portion. The -chain is situated mainly within the cell membrane – but transverses it 
four times so that both the amino- and carboxy- termini are cytoplasmic. 
Interestingly, and significantly, by the mid-1990s it became apparent that high 
affinity IgE receptors could be identified on the surface of immune effector cells 
besides mast cells and basophils (albeit at far lower densities) but that the -chain is 
not always necessary for the receptor to be expressed on some of these cell surfaces –
in fact it is usually absent on APCs (figure 2).
By the early 1990s researchers had been able to isolate complementary DNA (cDNA) 
coding for all three subunits in humans (Kinet et al. 1987;Kinet et al. 1988;Shimizu et 
al. 1988;Kuster et al. 1990;Kuster et al. 1992). They were able to use this information 
to predict the amino acid sequences of these proteins. Furthermore, by transfecting
part or whole of the cDNA sequences for the various chains into heterologous 
mammalian cell lines (e.g. the Chinese hamster ovary line), they were able to study 
the expression and function of the various components of the FcRI complex (Kochan 
et al. 1988;Miller et al. 1989;Kinet et al. 1988;Hakimi et al. 1990). In addition, even 
though determination of the crystal structure of the receptor (and particularly of the 
-chain bound to IgE) was still a few years away, this knowledge of the amino acid 
sequences allowed very accurate conceptual models of the architecture of the receptor 
to be developed (Padlan & Helm 1992). 
One consequence of the research investigating the structure of FcRI being done at 
that stage was the development of a number of well characterised monoclonal 
antibodies (mAbs) directed at discrete segments of the receptor’s component chains
(Riske et al. 1991;Rivera et al. 1988). These proved to be useful tools for researchers 
investigating the expression of this receptor on different cell types – in fact three of 
the studies described in this dissertation benefited from the availability of receptor 
specific mAbs.
1.5.1 The -subunit
The -chain is the subunit on which the IgE Fc segment binding domain is actually 
situated (Hakimi et al. 1990;Robertson 1993). It is a 45 kDa glycoprotein with a short 11
cytosplasmic tail of 33 amino acids (ending with the carboxy terminal) and a 20 
amino acid transmembrane domain but with most of the chain situated extracellularly
(181 amino acids) (Blank et al. 1989;Garman et al. 1998). The -chain belongs to the 
immunoglobulin superfamily.
The immunoglobulin superfamily includes many cell surface or soluble molecules 
that mediate recognition, adhesion or binding functions in the vertebrate immune 
system. Members of this superfamily share some structural homology but do not 
necessarily have similar functions. Although they probably share a common 
evolutionary pathway, they do not necessarily demonstrate genomic association –
indeed their genes are often on different chromosomes. The main characteristics of 
molecules in this family is that they possess at least one ‘immunoglobulin domain’ –
a region of 70-110 amino acids homologous to the V or C domains on 
immunoglobulins – with immunoglobulin folds (stabilised by conserved cysteine 
residues contributing to an intra-chain disulphide bonded loop) (Williams & Barclay 
1988). 
The amino acid sequences obtained from analysis of cDNA for FcRI predicted two 
disulphide-linked immunoglobulin folds in the extracellular portion of the -chain 
(from amino acids positions 51 to 93 and 132 to 176) (Padlan & Helm 1992). This 
therefore means that the extracellular -chain comprises of two immunoglobulin 
domains – which can be termed 1) and 2). By around 1993, the main IgE binding 
region on the FcRI had been mapped to the (2) domain (Mallamaci et al. 
1993;Robertson 1993) – but it was also apparent that the presence of structural 
elements within the (1) domain are also necessary to impart high affinity IgE 
binding activity (Mallamaci et al. 1993). By this time similar analytical work had 
been done on IgE and the FcRI binding site had been identified on the two C3 
domains of the Fc fragment (Basu et al. 1993;Beavil et al. 1993;Presta et al. 1994). 12
Figure 3:   Schematic representation of a tetrameric 
FcRI complex showing the two extracellular 
immunoglobulin domains of the  subunit– (1) and 
(2) – and the IgE binding site on these domains (from 
B.J. Sutton and H.J. Gould, Allergy and Allergic 
Diseases Ed. A. B. Kay)
The extracellular region of FcRI contains seven potential N-linked glycosylation 
sites which can bind carbohydrate moieties (Garman et al. 1998). In fact attached 
carbohydrates account for some 30-40% of a receptor’s weight (Kanellopoulos et al. 
1980;LaCroix & Froese 1993). However several studies have shown that this large 
carbohydrate presence does not interfere with the ability or the affinity of the receptor 
to bind IgE – thus indicating that the carbohydrate moieties are not located in the IgE 
binding site (Pecoud et al. 1981;Blank et al. 1991;Nettleton & Kochan 1995). Other 
studies would suggest however that glycosylation of the extracellular chain does have 
significant roles both in the intracellular transport of the chain to the cell surface (by 
enabling efficient folding of the -chain in the endoplasmic reticulum) and also at the 
cell surface by enabling the chain to be correctly orientated (Pecoud et al.
1981;Letourneur et al. 1995).
1.5.1.1 Structural analyses providing insights into the interaction between IgE 
and the -subunit of the FcRI
In 1998 Garman et al finally solved the crystal structure of the extracellular regions of 
the  chain of the IgE high affinity Fc receptor by using X-ray diffraction at 2.4 Ǻ 
resolution. They discovered a very acute bend between the two Ig-like domains, (1) 
and (2). The acuteness of this bend is almost unique when compared to other Ig 13
domain structures and it helps produce a large convex surface within the (2) domain 
(contiguous with the (1)(2) interface) that is involved in binding the IgE Fc 
fragment. Adjacent to this area is a prominent loop extending from the receptor 
surface. This loop is formed by an unusual arrangement of four exposed tryptophan 
molecules and forms a complementary contact surface for IgE, thereby conferring 
specificity for IgE (Garman et al. 1998). This analysis also confirmed that none of the 
seven densely glycosylated regions impinge on the IgE binding site.
Within the next four years two further high resolution x-ray diffraction analyses were 
published – in 2000, Garman et al went on to elucidate the structure of the Fc 
fragment of IgE when it is actually bound to the -chain of FcRI (Garman et al. 
2000) and in 2002 Wan et al published the detailed crystal structure of the Fc 
fragment of IgE (Wan et al. 2002). These studies finally helped provide feasible 
answers to two fundamental questions about the nature of this interaction – the reason 
for the unique 1:1 stoichiometry and the basis of the exceptionally slow dissociation 
rate when the two molecules actually interact.
The crystal structure of the Fc fragment determined by Wan et al demonstrated that 
its pair of C2 domains form a distinctive disulphide-linked immunoglobulin domain 
interface and are folded back asymmetrically onto the C3 and C4 domains. This 
causes an acute bend in the IgE molecule, resulting in a compact, tightly bent 
conformation (just as had previously been described by Zheng et al. in 1991). The 
structural implication is that there is a substantial conformational change involving 
this C2 hinge when the IgE molecule binds to its Fc receptor, FcRI, which makes it 
very difficult for the molecules to prise themselves apart leading to the exceptionally 
slow dissociation rate. However this C2 region may also allow bending of the 
antibody when attached to its receptor and thus allow the Fab domains to be 
optimally positioned to capture multivalent antigens (Wan et al. 2002).
The crystal analysis of the IgE-Fc–FcRI complex (Garman et al. 2000) revealed
two interactions site with the two C3 domains of the Fc fragment binding 
asymmetrically two distinct sites on the -chain: one to the convex Fc binding 
surface formed in the (2) domain and the other to the previously described loop 14
formed by the four exposed tryptophan molecules. This dual binding of both C3 
domains precludes further binding of the IgE molecule to any other Fc receptor –
resulting in 1:1 binding only.
Figure 4: Overview of the crystal 
structure of the IgE-Fc/FcRI
complex showing the dual IgE C3 
binding sites on domain 2 (D2) of 
the FcRI chain (which is depicted 
in blue) (from Garman et al. 2000).
Cross-linking of cell surface receptor bound IgE by multivalent antigens can induce a 
number of effector responses, depending on the nature of the cell. In mast cells, for 
instance, this surface binding of antigen can result in rapid secretion of preformed, 
granule stored mediators (such as histamine) and also initiate synthesis and 
subsequent release of lipid mediators and cytokines (Lowman et al. 1988;Toru et al. 
1998). In antigen presenting cells, on the other hand, the receptor bound antigen may 
be internalised and processed for presentation to other effector cells such as T cells
(Bieber 1996;Stingl & Maurer 1997). However the -chain has no significant 
signalling capacity and is therefore dependant on the availability one or more of it 
associated subunits (- or -chains) to set off well defined cascades of intracellular 
signal leading to cell activation. Although neither of these chains possesses intrinsic 
catalytic activity, both contain the ITAM sequence and are closely associated with 
cytoplasmic protein tyrosine kinases. Their roles in signal transduction are elucidated 
in section 1.5.3.
1.5.2 The -subunit and -subunits – structure, function and cellular 
expression
In the decade following the first description of the complete structure of the human 
FcRI by Blank and his colleagues in 1989 (Blank et al. 1989), huge strides were 15
made in defining the structure and function of the two other chains involved in the 
receptor complex.
The -chains are transmembranic polypeptides with each chain having a molecular 
weight of 7– 9 kDa. They exist as a homodimer which is actually identical to the -
subunit of FcRIII (CD16 – one of the low affinity Fc receptors for IgG) (Letourneur 
et al. 1991). The -chain complex is also found associated with other Fc receptors,
including FcRI (Ernst et al. 1993;Scholl & Geha 1993) and FcRI (Pfefferkorn & 
Yeaman 1994), on cells expressing these receptors. FcRI is also structurally closely 
related to the  and  chains of the T cell receptor (TCR) complex – for instance each 
-chain has 55% structural homology with the  chain (Kuster et al. 1990;Rodewald 
et al. 1991). In fact substitution of  chains in a TCR and FcRI by one another can 
still result in functional receptor complexes (Howard et al. 1990;Rodewald et al.
1991). 
The -chain has an unusual orientation as it traverses the cell membrane four times 
with both the C- and N- termini being on the intracellular side of the membrane 
(Kinet et al. 1988) (figure 2). It is a protein around 245 amino acids in length with a 
molecular weight of 26.5 kDa (Kuster et al. 1992). By the early 1990s it had also 
become apparent that whilst the -chain appeared to be a constitutive component of 
the FcRI on mast cells and basophils, there may be a naturally occurring variant of 
FcRI without the -chain. This possibility was first suggested by experiments 
involving co-transfection of genes for the three different FcRI chains into cell lines
and then inducing surface expression of the proteins. It was found that whilst the -
and -chains were always necessary for the receptor to be expressed on the cell 
surface, stable surface expression could be achieved without the presence of a -chain
(Miller et al. 1989;Kinet et al. 1991). It came as no surprise therefore when 
researchers soon found that FcRI expressed on cell types other than mast cells or 
basophils are usually of the 2 variety (i.e. they lack the -chain) (Bieber 1996).
The ITAM is present in both - and -chains but differs slightly in both chains. The 
ITAM in the -chain has a shorter segment between its first two tyrosines and in 16
addition has a third tyrosine which is absent in the -chains (Nadler et al. 2001). 
Furthermore the cytoplasmic protein tyrosine kinase Lyn (a member of the Src family 
of tyrosine kinases) is found closely, and preferentially, associated with the -chain
(Jouvin et al. 1994). In contrast the -chain ITAM tends to associate with the tyrosine 
kinase Syk (Jouvin et al. 1994). This differing pattern of tyrosine kinase association is 
believed to help explain an important difference in the roles of the two chains in 
signal transduction. The -chain appears to be the primary chain responsible for 
transmitting cell activation signals (Letourneur & Klausner 1991;Wilson et al. 1995). 
In contrast the -chain does not have autonomous cell activation capability but is an 
excellent amplifier of -chain mediated activation signals with a gain of five to seven 
fold (Lin et al. 1996;Scharenberg & Kinet 1997). Thus the two chains act 
synergistically when the tetrameric variant of FcRI is present (e.g. on mast cells) to 
provide a larger amplitude activation signal then produced by the trimeric complex on 
antigen presenting cells. This amplifier property of the -chain appears to be almost 
unique amongst the known component chains of MIRRs. 
1.5.3 A brief summary of signal transduction cascades initiated by FcRI
The FcRI has proved to be a paradigm of immune receptor initiated signalling 
events. The study of intracellular signalling pathways is a highly specialised field but
the complex signal transduction cascades generated by the FcRI are quite well 
understood by now and have been extensively reviewed elsewhere (Beaven & 
Metzger 1993;Beaven & Baumgartner 1996;Nadler et al. 2001). A detailed discussion 
of these events is beyond the scope of this dissertation. However some understanding 
of the sequence of events from antigen binding to cell activation is fundamental to 
appreciating the important role of this receptor in cells involved in allergic 
inflammation. Therefore a relatively brief description of the main events involved 
follows.
Multivalent antigens cross-linking IgE molecules bound to the -chains on FcRI in
seconds (Metzger 1992b). The next step is the phosphorylation of tyrosine residues in 
the intracellular tails of the receptor chains. The presence of the tyrosine kinase Lyn 
the cell membrane cause the rapid aggregation of these receptors within a couple of 17
is crucial for this process and, as has been described above, this is closely associated 
with the -chain. As a consequence of the tight receptor aggregation Lyn kinases do 
not just phosphorylate -chain tyrosine molecules, but are also able to 
transphosphorylate tyrosine residues in adjacent-chains. The associated Syk kinases 
also bind to these phosphorylated ITAMs and, significantly, Syk also becomes 
phosphorylated by Lyn. Phosphorylated Syk is much more active than 
unphosphorylated Syk – thus the presence of the -chain and its close association 
with Lyn provides a great boost to the signals generated by -chains. These 
phosphorylation events are also very rapid and are complete within 5 to 15 seconds of 
receptor cross-linkage (Pribluda & Metzger 1992;Suzuki et al. 1997). The signalling 
cascade then moves on from these receptor associated processes to a number of 
signalling pathways that are present within the cell. These usually involve either 
activation of other enzymes with resultant effects on cytoplasmic substrates or 
activation of ‘second messengers’ including activated signalling proteins and, 
particularly important, increased concentrations of intracellular calcium ion 
concentrations (Beaven & Baumgartner 1996). 
Although these signal pathways are present in most cells, the upstream signals 
generated by the receptor complex result in well defined effector responses which all 
happen within particular time frames. For instance migration of granules to the cell 
surface and subsequent exocytosis of preformed mediators such as histamine happens 
within seconds. Another fairly rapid sequence of signals results in the activation of 
phospholipases (such as PLA2, PLC, PLD). One consequence of these is the synthesis 
of the arachidonic acid derived mediators leukotrienes (this process takes several 
minutes) (Beaven & Metzger 1993). Another consequence is the activation of 
cytokine genes in the nucleus, transcription of these genes and production and 
secretion of these cytokines. This process can take several hours – although the 
release of inflammatory cytokines could be greatly speeded up if preformed cytokines 
were able to be stored in granules (a possibility that was investigated in one of the 
constituent papers of this thesis).  18
1.6 The Low Affinity Fc Receptor For IgE
There is a second type of cell membrane receptor for IgE that has binds the Fc portion 
of IgE with an affinity almost two orders of magnitude less than FcRI (with a Ka of 
10
7 M
-1). In contrast to all other known immunoglobulin receptors, the low affinity Fc 
receptor for IgE (FcRII or CD23) does not belong to the immunoglobulin 
superfamily. It is actually a C-type lectin (Bonnefoy et al. 1993a). Lectins are usually 
defined by their ability to bind carbohydrates in glycoproteins but FcRII binds IgE in 
a Ca
2+ dependent manner that does not in fact involve binding to the carbohydrate 
moieties of IgE (Vercelli et al. 1989a).  
IgE is not the only natural ligand for CD23. It binds to the glycosylated cell surface 
molecule CD21 (also known as complement receptor 2, CR2) (Aubry et al. 
1992;Bonnefoy et al. 1993b), as well as the CD11b and CD11c components of 
integrin receptor complexes (Lecoanet-Henchoz et al. 1995). As might be expected 
from this variety of natural ligands CD23 shows great functional diversity.
CD23 molecules were originally described on B-lymphocytes where, interestingly, 
they appear to be closely associated with HLA-DR molecules on the cell surface 
(Bonnefoy et al. 1988). There appear to be two membrane bound isoforms – CD23a 
is expressed constitutively on B-cells whereas CD23b expression is inducible by IL-4 
(and inhibited by IFN- on B-cells and several other immune effector cells, including 
macrophages, Langerhans cells, follicular dendritic cells, eosinophils and T-
lymphocytes (Yokota et al. 1988;Bonnefoy et al. 1993a;Lee et al. 1993). 
Significantly, CD23 molecules unoccupied by IgE can be cleaved off from cell 
surfaces by proteases such as metalloproteinase ADAM 10 (Hibbert et al. 2005; 
Lemieux et al. 2007).
CD23 molecules expressed on B-lymphocytes appear to have several functions which 
may be important in the IgE mediated inflammatory cascade:
enhances the antigen-presenting capacity of B-lymphocytes to T-lymphocytes 
(Pirron et al. 1990;van der Heidjen et al. 1993). 
 Binding of IgE / allergen complexes to membrane bound FcRII molecules greatly 19
 Membrane bound CD23 molecules, by ligating CD21 molecules on T-
lymphocytes, may also have a role in stabilising T- and B-cell cognate interactions 
(Bonnefoy et al. 1993b). 
 Both of these actions may help promote more efficient allergen specific T-
 CD23 facilitated IgE-mediated allergen presentation by B-cells has been 
demonstrated to help promote TH2 type responses in vitro (van der Heijden et al. 
1993). In an allergen challenge mouse model, it was shown that an anti-CD23 
mAb could also effectively inhibit production of the archetypical TH2 cytokines 
IL-4 and IL-5 in vivo (Coyle et al. 1996). 
 Membrane bound and soluble CD23 also appear to play important roles in 
regulating IgE synthesis. For instance, CD23 facilitated allergen presentation on 
B-cells significantly up-regulates allergen specific antibody synthesis –
interestingly of IgM and IgG classes as well as IgE (Heyman 2002). Soluble CD23 
also appears to play an important role in up-regulating IgE synthesis, possibly by 
coligating cell membrane IgE and CD21 (Hibbert et al. 2005).
 On the other hand, coligation of membrane CD23 and IgE molecules seems to 
down regulate IgE synthesis (Hibbert et al. 2005).
The possibility of an intriguing natural regulatory feedback loop is raised by the 
H
since the TH2 cytokine IL-4 is of course not just important for CD23 synthesis but is 
also vital for the isotype switching of B-cells towards IgE production (Vercelli et al. 
1989b;Aubry et al. 1992). 
1.7 Introduction to the four core papers of this thesis
Four papers are presented and discussed in the following chapters. All of these papers 
involved research into aspects of blood derived FcRI bearing cells. The title of each 
paper and a brief summary of the nature of the study described are given below.
lymphocyte responses (Getahun et al. 2005;van Neerven et al. 2006).
observations described above that CD23 may play a role in regulating T 2 responses 20
1.7.1 Expression of high affinity IgE receptors (FcRI) on peripheral blood 
basophils, monocytes and eosinophils in atopic and non-atopic subjects: 
Relationship to serum immunoglobulin E concentrations (Sihra et al. 1997a).
As has already been described above, by the mid 1990s it was becoming evident that 
cell types other than basophils and mast cells may have some degree of FcRI
expression. Expression of this receptor had been reported on some peripheral blood 
monocytes from both atopic and non-atopic subjects (Maurer et al. 1994;Reischl et al. 
1996). Intringuingly, there were also some reports of FcRI expression on blood 
eosinophils from subjects with hypereosinophilic syndromes as well as some tissue 
eosinophils at sites of allergic inflammation (Gounni et al. 1994a;Gounni et al
1994b;Humbert et al. 1996). Several fundamental questions remained unanswered 
including:
 What is the comparative receptor expression on these three cell types in 
individuals?
 Do blood eosinophils really express FcRI?
 Is there increased receptor expression in any, or all, of these three leucocytes in 
subjects with atopic diseases compared to non-atopic individuals?
 If so is this difference due to the particular atopic disorder (e.g. asthma, allergic 
rhinitis or atopic dermatitis) or, as had been demonstrated on basophils (by 
indirect methods some two decades previously), does receptor expression on 
these cell correlate positively with serum IgE?
Answers to these basic questions were necessary to begin to fully appreciate the 
diversity of roles the high affinity IgE Fc receptor could play in allergic disorders, but 
previously it had been difficult to perform such a study for the following 
technological reasons:
1. At that time there were no basophil specific markers which allowed 
identification of unseparated basophils in blood.
2. Monoclonal antibodies (mAbs) specific for the various components of the 
FcRI complex had only just been developed.
3. The technology of multi colour flow cytometry and cell sorting (which was 
used in this study) had only just become widely available. This is a powerful 21
and very sensitive tool which can rapidly assess thousands of events in solution 
(e.g. cells and/or molecular complexes etc) and accurately identify the events of 
interest even if they are just at single figure level. 
In the paper presented in Chapter 2, we were able to use dual colour flow cytometry 
to evaluate FcRI expression on unseparated peripheral blood mononuclear cells 
(PBMCs) and get a ‘side-by-side’ comparison of expression on all three cell types. In 
this study we also took advantage of two characteristic properties of basophils – their
uniquely high level of constitutive FcRI expression and the characteristic way they 
scatter light during flow cytometric analysis – to develop a novel way of identifying 
basophils in blood without having to purify them. 
  
1.7.2 Unstimulated peripheral blood basophils in atopic and non-atopic 
subjects express intracellular interleukin-4: detection by flow cytometry (Kon, 
Sihra et al. 1998).  
The second paper (in Chapter 3) made further use of the novel flow cytometric 
method of identifying unseparated basophils in peripheral blood described above to 
examine their potential to rapidly secrete stored cytokines (in particular interleukin-
4). Previously studies on purified basophils obtained from atopic subjects had 
demonstrated their capacity to secrete IL-4 after in vitro IgE stimulation (Brunner 
etal. 1993;Schroeder et al. 1994).
In this study, multi-colour flow cytometry was used to analyse whether unseparated 
basophils in PBMCs from atopic and non-atopic donors constitutively express 
intracellular IL-4 which could then potentially be released following FcRI cross-
linkage.
1.7.3 The effect of cyclosporin A on the allergen-induced late asthmatic 
reaction (Sihra et al. 1997b).  
The immunosuppressive agent cyclosporin A (CsA) had been shown both to reduce 
disease exacerbations and improve lung function in patients with severe 22
glucocorticoid-dependent asthma (Alexander et al. 1992) and also act as a steroid 
sparing agent in a similar group of patients (Lock et al. 1996). Whilst it was initially 
thought that its efficacy resulted mainly from its inhibitory effects on the secretion of 
pro-inflammatory cytokines from activated T-lymphocytes, evidence was 
accumulating that CsA has other actions which could also have therapeutic benefit in 
asthma. In particular it had been shown to rapidly and potently inhibit mediator 
release from FcRI bearing cells (mast cells and basophils) (Casolaro et al. 
1993;Triggiani et al. 1989).
This paper describes a randomised, double blind, placebo controlled cross-over study 
that evaluated the effects of pre-treatment with CsA on allergen induced early and 
late asthmatic responses (EAR and LAR, respectively). The EAR is thought to result 
mainly to result from the rapid release of pre-formed histamine and newly generated 
lipid mediators (such as cysteinyl leukotrienes) from FcRI bearing cells (mainly 
mast cells, possibly tissue basophils) following cross linkage of allergen specific IgE 
bound to the FcRI (Casale et al. 1987;Liu et al. 1991). In contrast, the LAR features
a characteristic inflammatory response which particularly involves T-lymphocyte 
activation, increased production of ‘eosinophil-active’ cytokines and accumulation of 
eosinophils in the bronchial mucosa (Bentley et al. 1997). The study described in 
Chapter 4 attempted an in vivo ‘dissection’ of the various possible mechanisms of 
CsA in asthma and tried to provide an answer to the question whether the observed 
inhibitory actions on FcRI bearing cells in vitro are indeed useful in this model of 
allergen induced asthma.
1.7.4 Effects of maintenance or cessation of prolonged allergen specific 
subcutaneous injection immunotherapy on humoral immune responses and cell 
surface IgE receptor expression in peripheral blood (Sihra et al. 2000). 
The efficacy of subcutaneous allergen specific immunotherapy (SCIT) for grass 
pollen seasonal allergic rhinitis is now well established – and a series of studies led 
by Professor Stephen Durham have been influential both in establishing its efficacy 
and also in elucidating the immunomodulatory effects of SCIT (Varney et al. 
1991;Varney et al. 1993;Walker et al. 1995;Durham et al. 1996;Durham et al. 1999). 23
A major change during SCIT treatment appeared to be a change in allergen specific 
cytokine responses from TH2 to TH1 type (Till 1997). However during SCIT 
treatment there are other observed changes in peripheral blood (Durham & Till 
1998;Till et al. 2004), including:
 attenuation of seasonal elevations in serum levels of allergen specific IgE;
 gradual decline in specific IgE levels;  
 increased concentrations of allergen specific IgG antibodies, so called ‘blocking 
antibodies’;
 decreased basophil reactivity in vitro to IgE dependent stimuli, presumed to be 
reflected in vivo by reduced amounts of mast cell or basophil derived mediators 
in nasal secretions, has also been described.
In a seminal study by Professor Durham (Durham et al. 1999), 27 subjects with 
seasonal allergic who had received continuous grass pollen SCIT for 3-4 years were
randomised, in blinded manner, either to continue receiving active IT or placebo 
injections for a further 3 years. It was found that there was no difference in symptom 
scores, medication use and cutaneous late phase responses between both groups at the 
end of this study period. Notably, improvements in all these parameters compared to 
baseline values had been maintained 6-7 years after initiation of SCIT even in the 
group who had not received active IT for 3 years. Furthermore there was evidence of 
persistence of the skewed cytokine profile from TH2 to TH1, with reduced numbers of 
IL-4 mRNA+ cells following cutaneous allergen challenge (with no difference 
between the two treatment groups) at the end of the study. Questions that remained to 
be answered included whether the humoral immunological changes associated with 
successful immunotherapy described above also persisted in these two groups of 
patients who had received 3 years of allergen specific IT whether or not they had 
continued to receive prolonged SCIT. Furthermore, is prolonged IT associated with 
changes in IgE receptor expression (both high and low affinity) on blood cells? 
In the study described in the final paper of this thesis (Chapter 5), blood samples were
obtained before and during the final pollen season of the study from all these 27 
patients as well as 2 control groups (one non atopic group and one group of subjects 
with seasonal allergic rhinitis who had never received SCIT) and comparative 24
analyses were performed for serum total IgE (immunoglobulin E) concentrations, 
serum concentrations of allergen (Phleum pratense) specific IgE and IgG, FcRI 
expression on basophils and monocytes and CD23 (the lower affinity receptor for 
IgE) expression on B-lymphocytes and serum concentrations of the soluble form of 
FcRI.25
Chapter 2
Cells Expressing FcRI  In Blood
2.1 Expression Of High-Affinity IgE Receptors (FcRI) On Peripheral
Blood  Basophils,  Monocytes,  And Eosinophils  In  Atopic  And  Non-
Atopic Subjects: Relationship To Total Serum IgE Concentrations
(published in the Journal of Allergy and Clinical Immunology 1997; 99: 699-706)J ALLERGY CLIN IMMUNOL  Sihra  et al,  701 
VOLUME 99, NUMBER 5 
Current atopic 
disease 
(no. of subjects) 
Concurrent 
treatment 
Asthma 10 
Seasonal rhinitis 7 
Perennial rhinitis 3 
Eczema 0 
Asthma 0 
Seasonal rhinitis 9 
Perennial rhinitis 8 
Eczema 0 
Asthma 6 
Seasonal rhinitis 2 
Perennial rhinitis 0 
Eczema 8 
Asthma 0 
Seasonal rhinitis 0 
Perennial rhinitis 0 
Eczema 0 
Bronchodilator 10 
Inhaled steroid 8 
Nasal steroid 2 
Antihistamine 0 
Bronchodilator 0 
Inhaled steroid 0 
Nasal steroid 0 
Antihistamine 2 
Bronchodilator 5 
Inhaled steroid 4 
Nasal steroid 1 
Topical steroid 6 
Antihistamine 4 
Nil 
expressing a characteristic side-scatter vs CD9-staining pattern) 
before this study began. For both mAbs, the saturating concen- 
tration for monocytes and basophils was 3 ~g/ml (per 1 x  106 
total PBMCs) and for eosinophils an average of 30 Ixg/ml (per 
1 ×  106 eosinophils). 
Study  design 
Peripheral venesection was performed on each subject, and 
20 to 25 ml of blood was collected in a heparinized syringe. At 
the same time blood was also collected for RASTs and quan- 
tification of total serum IgE concentrations by the CAP system 
(Pharmacia Diagnostics, Uppsala, Sweden). Five milliliters of 
6% dextran in Hanks' balanced salt solution was added to the 
heparinized blood, and erythrocytes were allowed to sediment. 
The buffy layer was then collected and mixed with an equal 
volume of RPMI-1640 medium (Sigma-Aldrich Company Ltd., 
Poole, Dorset, U.K.) before it was overlaid onto Ficoll-Paque 
(Pharmacia Biotech, Uppsala,  Sweden) and centrifuged for 
20 minutes at 20  ° C  and 1000 g.  Cells at the medium-Ficoll 
interface (PBMCs containing basophils, as well as lympho- 
cytes  and  monocytes)  were  collected  and  processed  sepa- 
rately from the cell pellet (containing granulocytes and any 
remaining erythrocytes). Both cell samples were washed in 
phosphate-buffered saline (PBS) before the erythrocytes in 
the  granulocyte pellet were  lysed  by using  10%  B.D.  lysis 
solution (Becton Dickinson Immunocytometry Systems, San 
Jose,  Calif.).  All  further  processing  of  the  samples  was 
performed at 4 ° C. 
The PBMC sample concentration was adjusted to  1  ×  106 
cells in 100  Ixl of PBS. Twenty microliters of the appropriate 
primary mAb (20 ixg/ml 22E7,  15-1, or isotype control in PBS 
containing 10% vol/vol human serum) was added (giving a final 
antibody concentration of 3 Ixg/ml). After a 30-minute incuba- 
tion  period,  the  samples  were  washed  twice  in  PAB  (PBS 
containing 0.5% wt/vol bovine serum albumin and 0.1% wt/vol 
sodium azide) and then stained with the secondary mAb (goat 
anti-murine  IgG 1 conjugated  to  PE)  diluted  1:40  with  10% 
human serum in PBS. A  further 30-minute incubation period 
was followed by two washes with PAB and a  final 15-minute 
incubation with 5  pJ of anti-CD14 FITC.  Granulocytes were 
treated almost identically except that the final concentration of 
primary mAb was 30 txg/ml per granulocyte sample containing 
1 ×  106 eosinophils, and the final stain was with 5 ixl anti-CD9 
FITC.  After  final washes,  the  samples were  ready  for  flow 
cytometry. 
Flow cytometry 
The samples were analyzed on a Coulter Epics Elite ESP flow 
cytometer and cell sorter (Coulter Corp., Hialeah, Fla.). Iden- 
tical gain settings were used for each sample, and the cytometer 
flow cell was fully aligned and calibrated with Immuno-Check 
fluorospheres (Coulter) before each run. This allowed direct 
and valid inter- and intraindividual comparisons. 
From early experiments, it became clear that every subject 
studied (normal and atopic) had a distinct population of cells 
(about 2% to 6% of PBMCs) that stained brightly with both 
anti-FceRI-e~  antibodies and had  a  characteristic side-scatter 
pattern between  lymphocytes  and  monocytes.  This group  of 
cells did not express surface markers such as CD3, CD14, and 
CD19, which identify other cell types within PBMC samples. 
With 22E7 staining, this cell population was sorted to 97%  +_ 
1% purity, and cytospins of the sorted cells were made. Staining 
with  May-Grtinwald-Giemsa stains  confirmed  that  all  these 
cells were  basophils.  This very specific method  of positively 
detecting basophils in blood by flow cytometry, which was used 
for this study, had many similarities to a previously described 
method,  which  used  side-scatter  and  surface-bound  IgE  to 
identify basophils)  6 
Monocytes were identified by their characteristic CD14 ver- 
sus side-scatter staining pattern: cell sorting confirmed that cells 
with this pattern were more than 97% pure monocytes. Simi- 
larly,  eosinophils were  identified by their characteristic CD9 
versus side-scatter pattern within the granulocyte sample. Data 
from  10,000  monocytes  and  eosinophils were  collected  and 
analyzed. 
Cellular expression of FceRI was quantified by determining 
the specific mean fluorescence (smf). This was the difference 
between the mean fluorescence intensity (mfi) of cells stained 
with 22E7 or  15-1  and the mfi of these cells stained with an 
isotype-identical irrelevant control antibody. Because saturat- 
ing  concentrations  of  the  primary  antibody  and  the  same 
secondary  antibody were  used,  this  figure  was  proportional 
either to the mean numbers of surface FceRI per cell (22E7) or 
mean numbers of Fc~RI unoccupied by IgE per cell (15-1). 
Although  only  single  samples  stained with  each  antibody 
were  analyzed  for  each  subject,  the  reproducibility  of  cell 
staining was assessed by staining eosinophils from one subject in 
quadruplicate  with  22E7  or  the  isotype  control  mAb  and 
determining the coefficients of variation of mils of these repli- 
cate samples. 
Statistical  analysis 
Data were  analyzed by using a  statistical package  (Minitab 
for Windows, Minitab Release 9.2; Minitab Inc., State College, 
Pa.). Nonparametric analytical tests were used: Kruskal-Wallis 
ANOVAR  analysis was  used  to  assess variability within the 
study population; and if this was significant, the Mann-Whitney 
U  test was used to analyze intergroup differences. Correlation 
coefficients were calculated by Spearman's method with correc- 
tion for tied values. For all tests, p  values less than 0.05 were 
considered significant. 34
2.2  Addendum  –  Further  Data  On  IgE  Occupancy  Of  FcRI  On 
Basophils And Moncytes
In the discussion of the paper presented in Section 2.1, it was mentioned that the use 
of a non-competitive (22E7) and a competitive (15-1) anti-FcRI mAb at saturating 
concentrations in our study provided a good estimate of the level of occupancy of 
FcRI by monovalent IgE. It was also stated that by assessing this estimated 
occupancy it became apparent that a greater proportion of FcRI chains were 
occupied on basophils and monocytes in atopic subjects than in non-atopic controls. 
However there were a number of assumptions involved in estimating occupancy by 
this method and therefore the method or data were not discussed further in the paper. 
Nevertheless it might be appropriate to describe these briefly at this stage since the 
importance, in these cell types, of the observation of a close inter-relationship 
between serum IgE and cell surface expression of the -chain of its high affinity 
receptor will be discussed in some detail in Chapter 6.
The concept that the difference between the specific mean fluorescence intensity 
(smf) of staining of receptors by these two mAbs might provide a measure of receptor 
occupancy arose from the initially puzzling observation that in contrast to 22E7, 
whose smf levels on both cell types increased in atopic individuals with elevated 
serum IgE concentrations, 15-1 specific staining tended, if anything, to be slightly 
higher in non-atopic subjects and was at times barely detectable in subjects with 
higher serum IgE concentrations (as described in the paper). The most logical 
explanation was that even as there must be greater numbers of FcRI expressed on 
these cells as IgE levels increase, more of these receptors must be bound to IgE – thus 
resulting in reduced 15-1 staining. 
As saturating concentrations of mAbs were used, the non-competitive mAb 22E7
could be assumed to bind to all FcRI chains whether occupied or unoccupied by 
IgE, whereas 15-1, the competitive mAb, would bind only to unoccupied receptors. 
The specific mean fluorescence values of binding to 22E7 and 15-1 for each subject 
observed in the study therefore could be assumed to represent, respectively, total and 
unoccupied receptor expression. By implication therefore, as the cytometric 35
evaluation was done using standardised conditions and each mAb had the same 
number of fluorochromes of similar brightness, receptor occupancy should be directly 
proportional to the difference between the smf of receptor staining on cells from the 
same individual with the two mAbs and therefore it could be estimated quite 
accurately by expressing the difference between the smf of 22E7 and 15-1 staining of 
basophils as a percentage of 22E7 smf. The validity of these assumptions was tested 
in a separate pilot experiment described below.
The aim of this pilot (or ‘proof of concept’) study was to investigate the hypothesis 
that 15-1 smf on both basophils and monocytes would increase and become 
comparable to 22E7 smf when receptor bound IgE was dissociated from the receptors. 
Peripheral blood mononuclear cells (PBMC) from 8 subjects (6 atopic and 2 non-
atopic) were studied and IgE was dissociated from FcRI by a modification of the 
acid elution technique first described by Pruzansky (Pruzansky et al. 1983). This 
method efficiently removes most (at least 95%) of the receptor bound IgE from the 
surface of living cells whilst maintaining cell structure and integrity.
The method, briefly, was that PBMC obtained from whole blood by the Dextran-
Ficoll gradient method (described in Section 2.1 – ‘Study Design’) were washed twice 
in PAG buffer (an isotonic organic buffer consisting of 25 mM PIPES buffer/0.1% 
human albumin solution/0.1% glucose), resuspended in PBS (phosphate buffered 
saline) and a sample taken for a cell count. Around 4 x 10
6 PBMC were then removed 
and left at 4
oC until the time came for staining with the FcRI specific mAbs for 
analysis (these were the untreated cells from which IgE had not been dissociated). The 
remaining PBMC were then recovered from solution by centrifugation and were then
subjected to the elution procedure by being resuspended in 5 ml 0.01M lactic acid (pH 
3.9) at room temperature. After 3.5 minutes the elution process was immediately 
stopped by the addition of 35 ml PAG buffer. Both the untreated and treated PBMC 
samples were now recovered from solution by centrifugation and washed twice in 
PAB (PBS containing 0.5% wt/vol bovine serum albumin and 0.1% wt/vol sodium 
azide) before being resuspended in PAB at a concentration of 1 x 10
6 PBMC per 100 
l. The cells then underwent the same triple stage staining procedure with mAbs that 36
is described in Section 2.1 – ‘Study Design’ and were then analysed by flow 
cytometry – again exactly as described in Section 2.1 – ‘Flow cytometry’. 
Most interestingly, the results of this study (shown in Figures 1 and 2 below) 
demonstrated that although, as expected, 15-1 smf was significantly less than 22E7 
smf on the untreated cells (both basophils and monocytes), after the removal of 
receptor bound IgE (by elution with 0.01M lactic acid) the smf of 15-1 staining 
indeed increased and became almost equivalent to that of 22E7. Moreover there was 
no significant difference between 22E7 smf on these cells pre- or post-dissociation,
implying that there was no significant receptor loss. 
Figure 1: Specific mean 
fluorescence values of basophil 
staining with 22E7 and 15-1 pre-
and post- dissociation of 
receptor-bound IgE by 0.01M 
lactic acid
Figure 2: Specific mean 
fluorescence values of 
monocyte staining with 22E7 
and 15-1 pre- and post-
dissociation of receptor-bound 
IgE by 0.01M lactic acid37
This study did therefore provide evidence to support the concept that the difference 
between the smf values for 22E7 and 15-1, expressed as a percent of 22E7 smf, would 
indeed provide a very good approximation of receptor occupancy on both basophils 
and monocytes in the subjects participating in the study described in Section 2.1.
The percent FcRI occupancy on basophils (calculated as above) for each subject was 
then plotted against that subject’s serum IgE concentration (figure 3). Even in non-
atopic subjects, with low serum IgE concentrations, the majority of receptors (about 
60%) were occupied and receptor occupancy increased as serum IgE concentrations 
increased until receptor saturation was observed at serum concentrations of greater 
than about 400 IU/ml. 
Figure 3:  Percent occupancy of 
high affinity Fc receptors by IgE 
on basophils from atopic and 
normal donors plotted against 
the logarithm of their total 
serum IgE concentrations
Furthermore, using this same method to calculate receptor occupancy on monocytes,
we observed once again that occupancy appeared to be related to serum IgE 
concentrations – albeit that this relationship was not quite as clearly obvious as for 
basophils (figure 4) – with receptor saturation appearing to occur at IgE levels of 
around 300-400 IU/ml and occupancy at lower serum IgE concentrations apparently 
much reduced in comparison to basophils.
Figure 4:  Percent occupancy 
of high affinity Fc receptors 
by IgE on monocytes from 
atopic and normal donors 
plotted against the logarithm 
of their total serum IgE 
concentrations38
Whilst this method of assessing receptor occupancy was of course somewhat 
convoluted and indirect, the findings described above suggested that the main 
observation of the study (that FcRI expression on basophils and, to a lesser but still 
significant extent, monocytes correlates closely with serum IgE concentrations) was 
more than mere coincidence. Indeed they suggested the strong possibility of a well-
defined causal relationship between IgE binding and FcRI expression on these cells –
a possibility that is considered further in Chapter 6. 39
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INTRODUCTION
The safety and efficacy of specific allergen injection immunotherapy (IT) in carefully selected patients 
with seasonal allergic rhinitis is now well established (1). Uncertainty still exists however as to the 
optimum duration of IT treatment and also whether IT has disease modifying potential. Moreover the 
underlying immunological mechanisms of IT are still unclear. Changes in several immunological 
parameters have been described in patients receiving IT but there is still debate as to the exact 
relevance of most of these changes to the observed symptomatic improvement (1-3).
Immunological changes in peripheral blood most consistently associated with allergen injection IT 
include attenuation of seasonal elevations in serum levels of allergen specific IgE (4) and, after several 
months of IT, a gradual decline in specific IgE levels (5). In contrast, concentrations of allergen specific 
IgG antibodies, so called ‘blocking antibodies’, tend to increase and have been associated with clinical 
improvement (6). Decreased basophil reactivity in vitro to IgE dependent stimuli (7), presumed to be 
reflected in vivo by reduced amounts of mast cell or basophil derived mediators in nasal secretions 
(8,9), has also been described.
IT affects cellular as well as humoral immune responses. IT has been shown to inhibit allergen-specific 
peripheral blood mononuclear cell proliferative responses (10,11). Successful allergen IT is associated 
with effective reductions in allergen-induced late phase reactions (LPRs) - both cutaneous (12) and 
nasal (13). Reductions in LPRs at both sites were associated with inhibition of infiltrating CD4+ T-
lymphocytes and activated eosinophils and significantly increased expression of mRNA for interferon-y 
(IFN-) (12,13). The results of these and other studies have led to the hypothesis that successful IT may 
act by modifying the pattern of cytokines produced at sites of allergic inflammation from a predominantly 
TH2 (e.g. interleukin-4, IL-4) towards a TH1 pattern (e.g. IFN-(14).
In a previously reported placebo controlled study of IT with Timothy grass pollen extract (Phleum 
pratense, Alutard SQ) in grass-pollen sensitive patients with severe seasonal rhinitis, significantly 
improved symptom scores and reduced medication requirements were observed in patients receiving IT 
(15). All participants in the original study then received active IT in open fashion for a further 3 years and 
symptomatic improvements continued to be demonstrated throughout the 3-4 years of IT. In addition, 
progressive and sustained reductions in pollen-induced cutaneous LPRs were observed during the 
treatment period although initial reductions in cutaneous early phase reactions (EPRs) were not 
maintained (16).56
The study was continued further with 27 of the original patients (who had by then received continuous IT 
for 3-4 years) being randomised, in blinded manner, either to continue receiving active IT (ITA) or 
placebo injections (ITP) for a further 3 years. The results of this study have been reported elsewhere 
(17). The most striking findings were that no significant differences were observed in symptom scores, 
medication use and cutaneous late phase responses between both groups at the end of this study 
period. Notably improvements in all these parameters compared to baseline values had been 
maintained 6-7 years after initiation of IT in the ITA and ITP groups even though latter had not received 
active IT for 3 years. 
In the present study we have investigated whether the maintenance or withdrawal of prolonged IT in 
these 27 subjects had any effect on particular immunological parameters in peripheral blood and have 
attempted to establish the possible relevance of any changes to the prolonged clinical efficacy of 
immunotherapy that was observed. Parameters specifically examined were serum total IgE 
(immunoglobulin E) concentrations, serum concentrations of allergen (Phleum pratense) specific IgE 
and IgG, FcRI (the high affinity receptor for IgE) expression on basophils and monocytes and CD23 
(the lower affinity receptor for IgE) expression on B-lymphocytes and serum concentrations of the 
soluble form of the chain of FcRI (sFcRI).
METHODS
Patients
The study was approved by the Ethics Committee of the Royal Brompton Hospital. Atopic patients were 
recruited from the Allergy Clinic at the Royal Brompton Hospital. The inclusion criteria for patients in 
both immunotherapy groups and the atopic control group (AC) were identical and have previously been 
described (15, 16). Briefly, these otherwise healthy patients all gave a history of severe seasonal rhinitis 
poorly controlled by conventional medication (anti-histamines, intranasal steroids and sodium 
cromoglycate) and all had a positive skin prick test (>5 mm wheal) to Timothy grass (Phleum pratense, 
Soluprick ALK, Denmark). Patients with chronic asthma were specifically excluded. The non-atopic 
controls (NC) had no symptoms suggestive of atopic disease and had negative skin-prick tests to a 
panel of 12 common aeroallergens. Full details of all four patient groups are given in table 1.
Study design
Twenty seven patients who had participated in the original study and had received either 3 or 4 years of 
immunotherapy continued to be assessed for a further 3 years for this study. In double-blind randomised 57
fashion 13 patients (the ‘ITA’ group) continued to receive maintenance allergen immunotherapy whilst 
14 patients (the ‘ITP’ group) received a placebo preparation for their maintenance treatment.  At the end 
of the study period, comparisons were made between the ITA and ITP groups and also two control 
groups containing 12 grass-pollen sensitive atopic rhinitics (AC) and 16 non -atopic subjects (NC).
Serum samples from the patients in the ITA and ITP were obtained at each summer and winter 
assessment visit during the 7 year study period (1989-1995) and stored at -80°C until the conclusion of 
the study when the concentrations of total IgE, specific IgE and specific IgG to Timothy grass pollen in 
these serum samples were determined. Additionally, FcRI expression on peripheral blood basophils 
and monocytes and expression of FcRII (CD23) on B cells were assessed by flow-cytometry using 
unseparated blood samples obtained from these subjects at the conclusion of the study. Finally stored 
serum samples taken before and during the final rhinitis season studied (1995) were used to determine 
soluble FcRI concentrations (sFcRl) in both IT groups. All these blood and serum parameters (apart 
from sFcRl in the NC group) were also evaluated in each AC and NC subject during the winter and 
summer of the final season.
Flow-cytometry
The following directly-conjugated monoclonal antibodies (mAb) were used for two and three colour flow -
cytometric analysis of the peripheral blood: CD20 fluorescein isothiocyanate (FITC) (Coulter), IgG1 FITC 
(Becton Dickinson), IgG2 isotypic control (Coulter), CD23 phycoerythrin (PE) (Coulter), CD14 PE 
(Becton Dickinson). 22E7 (isotype IgG1), a mAb specific for the -chain of the high affinity receptor for 
the Fc portion of IgE, FcRl was a kind gift from Drs. R. Chizzonite and J. Kochan, Hoffman-La Roche 
Inc., Nutley, NJ, USA. and was directly conjugated to FITC. The conjugation was performed by Cymbus 
Biotechnology Ltd, Hampshire, UK.
Aliquots of 100 µl of peripheral whole blood in EDTA were stained with the fluorochrome-conjugated 
antibodies and incubated in the dark at room temperature for 30 minutes. Red blood cells were then 
lysed and the remaining cells fixed using the ‘Multiprep’ system (Coulter). The cells were re-suspended 
in 250µl of 0.5% formaldehyde in an isotonic buffer (Isoton II, Coulter) prior to analysis on a Coulter 
Epics Elite flow cytometer and cell sorter (Coulter Corporation, Hialeah, FD). Identical gain settings were 
used for each sample and the cytometer flow cell was fully aligned and calibrated with Immuno-Check 
fluorospheres (Coulter) prior to each run. This allowed direct and valid inter- and intra-individual 
comparisons.58
Monocytes were identified by a combination of CD14 expression and characteristic side-scatter and 
data from 5000 monocytes collected and analysed. Basophils were identified by their characteristic 
22E7 staining and side-scatter appearances (as previously described (18)) and data from 1500-2000 
basophils were collected and analysed. B-lymphocytes were identified by gating on CD20+ staining cells 
within the lymphocyte population (identifiable by forward and side-scatter). Data from 2000 B-
lymphocytes were collected and analysed.
Cellular expression of FcRI on basophils and monocytes was quantified by determining the specific 
mean fluorescence (smf). This was the difference between the mean fluorescence intensity (mfi) of cells 
stained with 22E7 and the mfi of the cells stained with an irrelevant isotypic control antibody.
Additionally, the percentage of monocytes expressing FcRl and B-lymphocytes expressing CD23 
were analysed by the Immuno-4 software programme (Coulter). This programme used the Overton 
method of channel-by-channel histogram subtraction (19) to compare histograms generated by cells 
stained with the relevant anti-IgE receptor mAb and an identical number of cells stained with the isotype 
control mAb.
Serum total IgE, specific IgE and specific IgG measurements and sFcRl assay
Total IgE and phleum pratense specific concentrations of IgE were quantified by the UniCAP system 
(Pharmacia Diagnostics). Sera for quantification of allergen specific IgG and soluble FcεRIα were sent 
to the Laboratory of Medical Allergology,National University Hospital, Copenhagen. Specific IgG 
concentrations were measured by an enzyme linked immunosorbent assay and soluble FcRI levels 
were quantified by a sandwich immunoradiometric assay. 
Statistical analysis
Data were analysed using a statistical package (Minitab for Windows, Minitab Release 9.2, Minitab Inc., 
State College, PA). Non-parametric analytical tests were used - Kruskal-Wallis ANOVAR analysis was 
used to assess variability within the study population and, if this was significant, the Mann-Whitney U 
test was used to analyse inter-group differences. For intra-group paired data comparisons the Wilcoxon 
signed ranks test was used. Correlation coefficients were calculated by Spearman’s method with 
correction for tied values. For all tests, p values less than 0.05 were considered significant.59
RESULTS
The group characteristics are summarised in table 1. The ITA and ITP subject groups were well 
matched with regard to total serum IgE concentrations when they commenced the study in 1989 
(median values were 68 IU/ml for ITA, 77 IU/ml for ITP). Total IgE were also measured in the AC and 
NC control group subjects when they were recruited into the study in 1995. The IgE concentrations in 
the AC group did not differ significantly from the baseline measurements from the IT groups (median 
value 148.5 lU/mI) but concentrations in the NC group (median19.5 IU/ml) were significantly decreased 
when compared to the AC group (p= 0.02) and baseline values for the ITA group (p=0.03) but not the 
ITP group (p=0.08). There were no significant variations in serum total IgE levels in the ITA and the ITP 
groups in either winter or summer over the course of the study (figure 1). 
Table 1: Patient characteristics and baseline (1989 for ITA and ITP groups,1995 for control groups). 
serum total IgE and allergen specific IgE and IgG levels (median and interquartile ranges)
SUBJECT 
GROUPS
ITA ITP AC NC
NUMBER 13 14 12 16
GENDER (m:f) 8:5 7:7 7:5 9:7
MEAN AGE 
(range)
41 y
(19-65)
42 y
(31-58)
36 y
(22-56)
39 y
(22-71)
TOTAL IgE 
(IU/ml)
68
(47-102)
77
(7-1020)
148.5
(80-576)
19.5
(11.5-46.5)
ALLERGEN 
SPECIFIC IgE 
(IU/ml)
16.6 
(12.2-65.5)
9.3
(3-76)
32.2
(9.1-100)
0.0
(0.0-0.0)
ALLERGEN 
SPECIFIC IgG 
(IU/ml)
0.065
(0.053-0.08)
0.06
(0.045-0.085)
0.03
(0.02-0.043)
0.02
(0.0-0.02)
Figure 1:
Serum IgE levels in winter and summer months throughout the study period for both treatment groups 
(median and inter-quartile ranges).  1995 seasonal values for both control groups also shown.60
Figure 2:
Allergen specific serum IgE levels in off peak (winter) and peak (summer) pollen seasons during the 
study.  Final season values for both control groups also shown. * denotes values differ significantly         
(p ≤ 0.05) from baseline values. 
There were no significant differences in allergen specific IgE concentrations at baseline between both IT 
groups. However after 3-4 years of immunotherapy allergen specific IgE concentrations were 
significantly decreased compared to baseline values in the ITA and ITP groups. This significant 
reduction continued in the ITA group over the entire follow-up period (figure 2). Although this effect was 
still evident in the ITP group in the peak season estimations for 2 years following cessation of IT, 
specific IgE concentrations had returned to baseline values by the third year after ceasing active 
immunotherapy. In contrast, allergen specific IgG concentrations in both winter and summer were 
significantly increased from baseline in both IT groups after 3-4 years of immunotherapy and these 
increases were maintained in the ITA group. In the ITP group specific IgG returned to baseline values in 
the summer, but not winter, assessments but continued to remain significantly increased when 
compared to the AC group (figure 3).61
Figure 3:
Allergen specific IgG levels in serum in the ITA and ITP groups measured in winter and summer.
* denotes values differ significantly (p ≤ 0.05) from baseline values. Comparisons were also made with 
samples from atopic (AC) and non-atopic (NC) at the end of the study period.
There were no significant seasonal variations observed in the serum concentrations of sFcRl in the 
ITP or AC groups but sFcRl in the ITA group were significantly elevated during peak season when 
compared to pre-season measurements (p=0.02) (table 2). However there were no significant inter-
group differences in sFcRl levels, either pre- or peak season, between the three atopic groups.
Table 2: Median values (and interquartile ranges) of CD4+ and CD8+ counts, CD23 expression on B 
lymphocytes, FcRI expression on monocytes and soluble FcRI levels. * denotes values differ 
significantly (p ≤ 0.05) from baseline values
SUBJECT 
GROUPS
ITA ITP AC NC
 CD4 counts
(x10
9/l)
0.88
(0.6-1.14)
0.92
(0.76-1.07)
0.98
(0.64-1.13)
0.81
(0.73-0.96)
CD8 counts 
(x10
9/l)
0.43
(0.23-0.51)
0.3
(0.25-0.43)
0.37
(0.31-0.4)
0.33
(0.28-0.49)
CD23+ B cells (%) 36.3
(19.4-62.1)
36.3
(10.2-64.7)
45.7
(20.2-82)
26.3
(18.2-41.3)
CD23+ B cells 
(smf)
111.1
(45.7-309.5)
105.7
(24.9-216.6)
142.9
(44.7-345.7)
78.9
(50.2-139.0)
FcRI+ monocytes 
(%)
17.3
(14.4-30.8)
18.6
(8.0-34.2)
23.0
(15.5-28.8)
13.9
(9.2-23.4)
FcRI+ monocytes 
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Figure 4:
Relative expression of FcRI on blood basophils (expressed as the specific mean fluorescence) in the 
4 study groups
Figure 5:
a. b.
Graphs showing basophil FcRI expression (represented by the specific mean fluorescence of staining 
with 22E7) in all 27 subjects who received IT against (a) their total serum IgE concentrations or (b) 
allergen specific serum IgE concentrations. Solid circles are subjects in ITA group and open circles are 
those from the ITP group.
There was no significant difference between basophil FcRI expression (measured as the specific 
mean fluorescence of staining with the 22E7 monoclonal antibody) in either of the group of subjects who 
had received prolonged immunotherapy (ITA and ITP) and the control atopic subjects. As anticipated 
however, basophil FcRI expression was significantly elevated in all three atopic groups when 63
compared to that in the normal control group (figure 4). There was a significant positive correlation 
(r=0.8, p<0.001) when basophil FcRI expression  in subjects from both groups that received IT groups 
was compared to their serum total (but not allergen specific) IgE concentrations (figure 5). Interestingly, 
there was also a positive correlation between sFcRI and total IgE concentrations when the data from 
these 2 groups were similarly combined (r=0.605, p=<0.01) but only a weak positive correlation between 
sFcRI and allergen specific IgE concentrations (r=0.45, p=0.02).  There were no significant 
differences between subjects receiving active or placebo IT in FcRI expression on monocytes or FcRII 
expression on B-lymphocytes. 
SUMMARY
1. There were no significant variations in serum total IgE levels in the ITA and the ITP groups in 
either winter or summer over the course of the study ;
2. Serum allergen specific IgE was decreased in summer within the first year of commencing IT 
and remained significantly reduced whilst subjects continued to receive active IT. However 
summer allergen specific IgE levels no longer significantly differed from baseline 3 years after 
discontinuing active IT;
3. Allergen specific IgG concentrations in both winter and summer were significantly increased 
from baseline in whilst subjects received active IT. Allergen specific IgG returned to baseline 
values in the summer, but not winter, assessments when active IT was discontinued;
4. There were no significant changes in cellular FcRI expression on basophils and monocytes 
or FcRII  expression on B-cells;
5. Soluble FcRI levels did increase during the summer season in patients receiving active IT in 
the one year they were measured (the final year of the study).
This study and its results will be discussed in detail in Chapter 6, section 6.5.64
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Chapter 6
Discussion
6.1  Prologue
The main body of this thesis has consisted of four papers (three published) describing 
original work that was done a few years ago. In the following sections, these studies 
will be put in context, with a discussion of how their observations and conclusions 
have been taken forward in subsequent years.
6.2 Studies Investigating Peripheral Blood Cells Expressing FcRI
The paper in Chapter 2 (Sihra et al. 1997a) was the first published direct comparative 
study of FcRI expression on basophils, monocytes and eosinophils, three blood cell 
types that may have potentially significant roles in initiating and maintaining allergic 
inflammation (discussed below). The study included 28 well characterised subjects 
with atopic disorders (asthma, rhinitis or dermatitis) as well as 10 non-atopic controls. 
The inclusion of such a large number of subjects allowed meaningful comparisons to 
be made between FcRI expression on these cell types and serum immunoglobulin E 
(IgE) concentrations.  We were able to confirm the close linear correlation between 
basophil FcRI expression and serum IgE concentrations first observed by Malveaux 
and colleagues (using indirect methodology) almost two decades previously
(Malveaux et al 1978). Intriguingly there was also a less strong, but still significant, 
positive correlation between FcRI expression on monocytes and serum IgE 
concentrations. The other main finding was that FcRI expression on eosinophils 
was detectable in only a few atopic subjects and, when these receptors were 
detectable, the level of expression much lower than on either of the other cell types. 
The observations described in our paper were almost replicated subsequently in a 
similar study (Saini et al. 2000) performed at the Johns Hopkins Allergy and Asthma 
Centre by the group led by Donald W MacGlashan (which is a group that has been 67
prolific in investigating regulation of FcRI expression on basophils). Their study 
used a very similar protocol to ours to examine FcRI expression on blood 
basophils, monocytes and eosinophils from subjects with a wider variety of conditions 
(non-atopic, allergic asthma, atopic dermatitis, hypereosinophilic syndromes, hyper 
IgE syndromes, helminth infestation or IgE myeloma) and also tried to correlate 
receptor expression with serum IgE levels. They too found a strong positive 
correlation between basophil FcRI surface expression and serum IgE 
concentrations (r=0.67, p < 0.01). However, although they observed higher expression 
of FcRI on monocytes in atopics, they did not find a significant correlation between 
monocyte FcRI expression and serum IgE overall. They only detected eosinophil 
FcRI expression in one subject with an IgE myeloma.
In the following sub-sections other studies that have been published subsequent to our
paper and specifically took forward or expanded our observations of FcRI expression 
on each of these three cell types are discussed.
6.2.1 Regulation of FcRI expression on basophils
As has already been described, a close positive correlation has been observed between 
surface FcRI expression and serum IgE levels. Furthermore it appears that the 
majority of receptors expressed on basophils are occupied by IgE molecules. As 
described in Section 2.2, receptor occupancy was estimated in our study from the 
observed intra-individual difference between the specific mean fluorescence intensity 
(smf) of receptor staining with two anti-FcRI mAbs (22E7, a non-competitive mAb 
that can be assumed to binds to all FcRI chains whether occupied or unoccupied by 
IgE and 15-1, a competitive mAb that binds only to unoccupied receptors).  It was 
found that even in non-atopic subjects with low serum IgE concentrations, the 
majority of receptors (about 60%) appeared to be occupied. Furthermore receptor 
occupancy appeared to increase as serum IgE concentrations increased until receptor 
saturation was observed at serum IgE concentrations of greater than about 400 IU/ml. 
Once again, just as with the correlation of FcRI expression with serum IgE levels, 
these observations of increasing occupancy related to serum IgE with saturation 68
kinetics were strikingly similar to the observations described previously by Malveaux 
(Malveaux et al. 1978). Taken together, the observations that basophils from 
individuals with higher serum IgE concentrations tend not only to have greater 
numbers of FcRI on their surfaces but also have a greater proportion of these surface 
receptors actually occupied by IgE would imply that the observed association between 
serum IgE and basophil FcRI expression is not merely coincidental. One plausible 
explanation that would be consistent with all these observations would be that there is 
a causal relationship between serum IgE and surface FcRI expression on circulating 
basophils – and this could perhaps result from receptor bound IgE somehow 
stabilising the receptors at cell surfaces.
Further evidence for the emerging concept that serum IgE could be a key modulator 
of cell membrane FcRI expression on basophils became available at around this time 
from early clinical studies of a novel and exciting therapeutic agent – omalizumab (or, 
as it was known at that time, rhumAb-E25). This is a humanised, chimeric 
monoclonal anti-IgE antibody. As it binds to the C3 domain of IgE (the FcRI
binding domain), it can only bind to free (i.e. not receptor bound) IgE. Therefore it is 
not anaphylactogenic (Presta et al. 1993;Saban et al. 1994). Unlike its binding to the 
FcRI chain, an IgE molecule can bind to two omalizumab molecules (and vice 
versa). In fact it has been demonstrated that this interaction can result in stable small 
(often cyclic hexamers), biologically inert complexes (Liu et al. 1995;Fox et al. 1996). 
Early phase 1 studies demonstrated that serum free IgE levels fall rapidly to less than 
10% of pre-infusion levels within minutes of an intravenous infusion of omalizumab, 
and that this reduction of free IgE levels is maintained with repeated regular infusions 
but gradual returns to baseline levels over a number of weeks after discontinuation of 
infusions (Fick 2002). The phase 1 studies therefore provided an ideal opportunity to 
assess the effects of changing IgE levels on basophil FcRI expression.  
In a study of 15 atopic patients who had been receiving regular infusions of rhumAb-
E25 (omalizumab) for 3 months, MacGlashan et al observed that serum free IgE 
levels had decease to less than 1% of pre-treatment levels. They prepared enriched 
basophil preparations from peripheral blood and used flow cytometric analysis of 69
mean fluorescence intensity with 22E7 to analyse basophil FcRI expression. 
Further quantification of basophil receptor densities was done by measuring eluted 
total and BPO-specific IgE (after pre-saturating receptors in vitro with 
benylpenicilloyl (BPO)-specific IgE which can only bind to receptors unoccupied by 
IgE). The investigators found that the median number of FcRI per basophil had 
decreased from 220000 to 8300 in their group of 15 subjects (Macglashan et al. 1997). 
These subjects continued to receive rhumAb-E25 infusions for a total of 46 weeks and 
free IgE and basophil bound IgE levels, as well as basophil FcRI expression, were 
re-evaluated within six to eight weeks of discontinuation of infusions (Saini et al. 
1999). Serum free IgE levels rose gradually by almost five-fold to around 16% of pre-
treatment levels by eight weeks after discontinuation of rhumAb-E25 infusions. 
Specific mean fluorescence of basophil bound IgE and 22E7 binding, assessed by 
flow cytometry, increased in parallel with serum free IgE levels. Furthermore, using 
the quantitative technique described above, basophil FcRI receptor numbers had 
returned to above 80% of pre-treatment levels. Finally, the investigators purified 
basophils from 11 of these subjects at the discontinuation of the infusions (i.e. with 
low levels of FcRI expression) and cultured them in vitro for 7 days in the presence 
or absence of IgE. Analysis by flow cytometry demonstrated significantly increased 
cell bound IgE and FcRI expression on cells cultured in the presence of IgE 
(whereas there was decreased expression in those cultured without IgE). 
Taken together, these studies quite elegantly demonstrated that the dramatic 
reductions in serum free IgE achieved by the ability of omalizumab to form bind with 
circulating IgE were associated with decreased basophil IgE and FcRI expression 
and that when serum IgE levels were allowed to increase once more (by discontinuing 
omalizumab), FcRI and cell bound IgE expression both increased again. These 
observations provided further supportive evidence that, at least on basophils, FcRI
expression seems to closely follow changes in IgE levels and therefore it is highly 
likely that IgE is the key regulator of FcRI expression on these cells.70
The obvious question that arose from these observations is “how does IgE regulate 
cell surface FcRI expression?” There could be a number of possible mechanisms, 
including:
 Regulation of FcRI synthesis by IgE (possibly involving regulation of gene 
transcription, stabilisation of transcripts or translation into protein of the various 
FcRI constituent subunits);
 Regulation of  intracellular processing and transport of FcRI chains by IgE-
mediated signalling;
 The binding of IgE by FcRI stabilises the receptor in the cell membrane.
Borkowski and her co-workers attempted to evaluate each of these hypotheses using 
two different cell lines in which they had transfected the cDNA of the subunits of the 
human FcRI receptor. Neither of these cell lines were of mast cell or basophil 
lineage so the observations they made are not necessarily limited to either of these cell 
types. By disabling various parts of the intracellular machinery (such as signal 
transduction pathways, gene transcription promoters, intracellular protein transfer etc) 
in these cell lines they were able to assess the minimal requirements for IgE mediated 
regulation of surface FcRI (Borkowski et al. 2001). They found that upregulation of 
surface FcRI expression by IgE did not depend on intracellular signalling or 
increased gene transcription, mRNA expression for the three receptor chains or 
intracellular protein levels. Furthermore IgE mediated upregulation of surface FcRI
was similar in cell lines deficient of cDNA for the -chain (i.e. upregulation of 2
receptors by IgE was as efficient as 2 receptors in these transfected cell lines). 
They concluded that the minimal requirement for regulation of FcRI on the cell 
surface is simply the degree of IgE binding by the -chain and that the main 
mechanism underlying this appears to be the stabilisation of the receptor within the 
cell membrane by IgE, which prevents re-internalisation and degradation of the 
receptor. 
They suggested quite a plausible model involving a continual turnover process of 
FcRI between the membrane and a preformed intracellular receptor pool fed by a 
continued basal level of protein synthesis (which is not upregulated by IgE) and 
cytoplasmic degradation of some receptors. In this model, binding of IgE to surface 71
FcRI chains considerably slows down, if not stops, the process of internalisation of 
the receptor and therefore greatly increases the number of cell surface receptors.
The Borkowski study of course used transfected cell lines. MacGlashan et al 
attempted to answer the same question specifically in human basophils (MacGlashan
et al. 2001). They used information derived from a series of experiments on enriched 
human basophil preparations as well as mathematical models to investigate whether 
IgE upregulates FcRI expression by regulating synthesis or by preventing receptor 
loss from the cell membrane. In one experiment they reduced receptor occupancy by a 
very short lactic acid treatment. This only removed FcRI bound IgE. They found 
that removing receptor bound IgE resulted in accelerated loss only of the receptors 
that were now unoccupied, with no loss of occupied receptors. Moreover there was no 
receptor loss when there was 100% receptor occupancy by IgE. They also found that 
the presence or absence of IgE had no impact on mRNA expression for any of the 
three chains of FcRI. Furthermore using pulse-labelling with 
35S methionine, they 
found that the rate of protein synthesis remained constant and was independent of the 
presence or absence of IgE. The conclusion of this complex study was similar to that 
of the Borkowski study i.e. they confirmed that FcRI surface expression on 
basophils is regulated by receptor bound IgE and that it appears to do this primarily 
by controlling the loss of receptors from the cell membrane with no impact on protein 
synthesis, which remains constant. 
6.2.2 Expression and regulation of FcRI on monocytes and monocyte derived 
dendritic cells in the blood
As discussed in Chapter 2.1, FcRI expression on monocytes in our group of atopic 
and non-atopic subjects showed a significant positive correlation to serum IgE levels. 
Furthermore, using the same method of calculating occupancy on monocytes as used 
for basophils (described in detail in Section 2.2), we observed that occupancy once 
again appeared to be related to serum IgE concentrations – albeit that this relationship 
was not quite as clearly obvious as for basophils – with receptor saturation appearing 
to occur at IgE levels of around 300-400 IU/ml and occupancy at low serum IgE 
concentrations seemingly much reduced in comparison to basophils. Once again, just 72
as with basophils, these observations raised the possibility that receptor bound IgE 
may regulate FcRI expression on the surface of monocytes. 
A study by Reischl and colleagues also looking at FcRI expression on monocytes 
from 58 non-atopic subjects was published at around the same time as our study 
(Reischl et al. 1996). They detected FcRI on monocytes from all subjects (median 
18% of FcRI+ monocytes, range 2– 66%) but most of the receptors on these ‘non-
atopic’ monocytes were unoccupied by IgE in contrast to monocytes from atopic 
subjects which showed higher receptor occupancy. The researchers then went on to 
examine whether they could stabilise or upregulate FcRI expression on these ‘non-
atopic’ monocytes. They found that FcRI expression was lost on cells cultured 
overnight in conventional culture medium in the absence of IgE but that overnight 
culture with IgE resulted in increased FcRI expression and IgE binding. Interestingly 
culture in the presence of IL-4 had no effect on receptor expression. 
This last finding of IL-4 not being effective at upregulating FcRI expression 
contrasted with a study published some five years later (Gosset et al. 2001). In this 
study, blood monocytes from atopic asthmatics (some of whom had received 
glucocorticoid therapy) and from non-atopic controls were studied. Once again 
monocyte FcRI expression was increased in the untreated atopic subjects compared 
to non-atopic controls – but of interest was the observation that FcRI expression on 
monocytes in the group of atopics who had received steroid therapy was similar to 
that on the control subjects. The monocytes were than cultured in vitro in the presence 
or absence of IL-4, IL-13 or GM-CSF and it was found that there was a dose-
dependent increase in FcRI chain expression on monocytes cultured with IL-4 or 
IL-13, but not GM-CSF, in both the atopic and non-atopic group. This was associated 
with an upregulation of -chain but not -chain mRNA. These effects were inhibited 
by the presence of glucocorticoid. The findings of this study also contrasted with the 
basophil studies, which had not found enhanced FcRI expression to be associated 
with cytokine induced upregulation of mRNA for any of the FcRI chains. Therefore, 
although the presence of IgE once again seems to be important for monocyte FcRI
expression, it appears that the ‘atopic state’ (specifically the presence of the TH2 73
cytokines IL-4 and probably IL-13) may well be an important extra factor modulating 
the expression of the receptor on APCs by upregulating synthesis of the -chain.
High affinity Fc receptors on monocytes and other antigen presenting cells (APCs) 
differ from those on mast cells and basophils in that they lack the -chain (Bieber 
1996). Almost as soon as FcRI were detected on monocytes, it was reported that they 
were functional – with signal transduction, increased intracellular Ca
2+ and 
prostaglandin E2 release resulting from cross-linking receptors (Maurer et al.
1994;Takenaka et al. 1995). Moreover, and perhaps more significantly, it was 
demonstrated that the efficiency of allergen presentation to T-lymphocytes by 
monocytes was increased 100- to 1000-fold in vitro if the allergen was targeted to 
FcRI on thesecells via allergen-specific IgE (Maurer et al. 1995) – a concept known 
as antigen focusing. Other actions that have been shown to result from cross-linking 
of FcRI on monocytes include induction of the transcription factor NF-B (with 
subsequent synthesis and release of the pro-inflammatory cytokine TNF- and the 
chemokine MCP-1) (Kraft et al. 2002) and prevention of monocyte apoptosis 
resulting from enhanced expression of the anti-apoptotic molecules bcl-2 and bcl-xl 
(Katoh et al. 2000).  
Even given all these potential pro-inflammatory actions of FcRI bearing monocytes, 
perhaps the most exciting development in the mid-nineties was the observation that 
blood monocytes are not necessarily terminally differentiated cells but can, given the 
right conditions, differentiate into the ‘professional’ antigen presenting cell, the 
dendritic cell (DC).  Dendritic cells are probably the most potent inducers of primary 
antigen-specific immune response (Banchereau & Steinman 1998) but the relative 
paucity of these cells in tissues and their varying phenotype during their life cycle 
hampered study of their ontogeny and functions until the last decade, when it became 
apparent that at least one major subtype of DCs actually has a myelomonocytic 
lineage (reviewed by Peters et al (Peters et al. 1996)). 
Several investigators observed that when monocytes are cultured in vitro in the 
presence of both IL-4 and GM-CSF, they terminally differentiate into cells that have 
the morphological and phenotypic characteristics of immature DCs (known as 74
monocyte derived DCs) (Kiertscher & Roth 1996;Pickl et al. 1996;Chapuis et al. 
1997;Palucka et al. 1998). Cells possessing the phenotypic characteristics of these 
immature (or monocyte derived) DCs were also identified in vivo in the peripheral 
blood of normal and atopic subjects (Maurer et al. 1996) – in fact we too were also 
able to identify them with our flow cytometric technique involving 22E7 staining and 
side scatter (shown in figure 1a in Section 3.1) (Kon, Sihra et al. 1998). These cells 
differ from monocytes as CD14 expression is greatly reduced or absent but expression 
of MHC Class II molecules, such as HLA-DR and HLA-DQ, is greatly enhanced.  
Other markers include increased expression of CD1a, CD40 and CD86 – but, most 
significantly from the point of view of allergen focusing, they also have increased 
expression of FcRI chains compared to monocytes (although less intensely so than 
basophils). Maurer et al showed that, as on other APCs, the FcRI expressed on blood 
DCs are of the trimeric, 2, form (Maurer et al. 1996). They further observed that 
not only did these blood DCs demonstrate proficiency as stimulators of primary 
immune responses (as assessed by their capacity to induce proliferation of allogeneic 
naive CD4+ T-lymphocytes), but that they also enhanced secondary, FcRI/IgE-
dependent, allergen specific T-cell proliferation almost 10 times more efficiently than 
monocytes.
More recently it has become apparent that there are in fact two distinct subsets of 
dendritic cells in human blood (Robinson et al. 1999), together representing just about 
0.3% of total blood leucocytes. These subsets are morphologically and phenotypically 
distinct and have been termed myeloid and plasmacytoid DCs (mDC and pDC). 
Immature mDCs are virtually identical to the monocyte derived DCs described above 
and have high levels of surface expression of myeloid markers such as the integrin 
CD11c and the C-type lectin CD207 as well as the co-stimulatory molecules CD40 
and CD86. Plasmacytoid DCs, on the other hand, are morphologically similar to 
plasma cells and, in contrast to mDC,  have no expression of CD11c but high
expression of other markers such as CD123 (the -chain  of the interleukin-3 
receptor) and, uniquely, a lectin recognised by a monoclonal antibody BDCA2 
(Schuurhuis et al. 2006). Particularly in atopic subjects, both the mDC and pDC 
subsets in blood express FcRI on their surfaces (Foster et al. 2003;Stary et al. 2005). 75
Both DC subsets also express different sets of Toll like receptors (TLR) – a family of 
highly conserved pattern recognition receptors (ten identified to date) that are crucial 
for innate immunity as they directly recognise conserved molecular patterns across 
different classes of pathogens and mediate cell activation (Kapsenberg 2003). Human 
mDCs express all TLR except TLR7 and TLR9, both of which are preferentially 
expressed on pDCs (Schuurhuis et al. 2006). In recent years, a great deal of interest 
has focused on trying to understand how antigenic ligation of these different types of 
TLRs on DCs sets in motion a sequence of events that can result in development of 
different antigen specific T-lymphocyte responses – either TH1 or TH2 immunity or 
regulatory T-cell responses (Kapsenberg 2003;Schuurhuis et al. 2006). It has become 
increasingly evident that whilst DCs are important sentinel cells, linking innate and 
adaptive immune responses, they are also pivotal in directing and modulating T-cell 
responses (Kapsenberg 2003;Abbas & Sharpe 2005;Novak & Bieber 2008). A brief 
synopsis of current understanding of this vital role regulatory role is provided in 
Section 6.6.
Most dendritic cells actually reside in tissues at sites in the body where pathogens 
may first be encountered – the skin, gut and respiratory tract. Several different tissue 
specific types of DC, both of myeloid and plasmacytoid lineage, have been identified 
(Novak et al. 2004) but it has become apparent that many of these DCs in the skin, 
nasal and oral mucosa as well as the lower respiratory tract are relatively immature 
myeloid lineage cells with high levels of surface FcRI expression, particularly in 
atopic individuals (Semper et al. 1995;Allam et al. 2003;Stary et al. 2005;Allam et al. 
2006).
Unfortunately characterisation of peripheral blood dendritic cells happened too late 
for them to be included in our study looking at the relationship between serum IgE 
and FcRI expression on peripheral blood cells (Section 2.1). In fact it was not until 
2003 that substantive evidence was available of a strong positive linear correlation 
between FcRI expression on both subsets of blood DCs and serum IgE levels (Foster 
et al. 2003). However prior to that there was indirect evidence suggesting such an 
association, including Maurer’s observation of increased receptor expression on 
circulating DCs from atopic, but not non-atopic, donors (Maurer et al. 1996). 76
Furthermore, whilst the process of in vitro differentiation of DCs from monocytes 
(with IL-4 and GM-CSF) results in enhanced intracellular accumulation of FcRI
chains in cells from all subjects, only cells from atopic donors seem to upregulate 
synthesis of the -chain, which is of course necessary for surface expression of the 
receptor (Novak et al. 2003). The ability of IL-4 to upregulate FcRI synthesis with 
increased intracellular accumulation in newly differentiated DCs has been confirmed 
by at least one other study (Geiger et al. 2000). Finally, another omalizumab study, 
this time in subjects with seasonal allergic rhinitis who received a six week course of 
infusions, provided conclusive evidence that, as for monocytes and basophils, free IgE 
does play an important role in modulating FcRI expression on blood DCs as 
omalizumab induced decreases in serum IgE levels were associated with significantly 
decreased FcRI expression on blood DCs (to a similar extent as decreases in basophil 
FcRI expression) (Prussin et al. 2003). 
In summary, therefore, there is now conclusive evidence that APCs in peripheral 
blood (specifically monocytes and immature dendritic cells, which are likely 
monocytes derived) can express the trimeric form of the FcRI. However, in contrast 
to basophils (and mast cells), expression of the receptor is not constitutive but is 
inducible – with the number of cells expressing the receptor as well as cell surface 
density being increased in atopic individuals. It appears that IL-4 at least (and 
probably IL-13) is necessary for upregulation of synthesis of the - and -chains in 
atopics. However it is likely that there is a recirculating process between the 
intracellular pool of the receptor and the cell membrane with IgE stabilising surface 
expression, just as in basophils.
6.2.3 FcRI on eosinophils in allergy
The presence of high affinity IgE receptors on eosinophils was first described on cells 
obtained from patients with hypereosinophilic syndromes (Gounni et al. 1994b). By 
the time the paper presented in section 2.1 was published, FcRI immunoreactive 
eosinophils were being identified in tissue from several sites of allergic inflammation 
– including bronchial biopsies from asthmatics (Humbert et al. 1996) and 
bronchoalveolar lavage fluid after segmental allergen challenge (Rajakulasingam et 77
al. 1998), nasal mucosa after allergen induced rhinitis (Rajakulasingam et al. 1997)
and in skin biopsies from subjects with allergen induced late phase cutaneous 
reactions (Barata et al. 1997). In the last study mentioned skin eosinophils also 
expressed mRNA for all three FcRI subunits.
The contrast between the reported increased levels of FcRI expression in tissue 
eosinophils at sites of inflammation and that in blood eosinophils reported in our 
study led to three obvious questions:
1. Does the process of migration of circulating eosinophils into the extracellular 
matrix at inflamed sites and subsequent interaction with tissue factors such as 
cytokines and fibronectin result in a change of surface phenotype with 
upregulation of FcRI expression in the cell membrane?
2. If tissue eosinophils do express surface receptors (albeit at very low levels when 
compared to basophils and even antigen presenting cells) are these receptors 
functional? If so what cellular actions do they contribute to?
3. Could it be that the techniques used to analyse tissue eosinophils 
(immunocytochemistry or Western blot analysis) were actually identifying 
FcRI chains stored intracellularly rather than surface proteins? Perhaps the 
observations in tissue cells were just artefactual and tissue eosinophils have no 
greater degree of surface FcRI expression than blood eosinophils. Certainly, in a 
preliminary experiment for the study described below (Smith et al. 2000) in which 
we analysed blood eosinophils after their cell membranes were permeabilised by 
saponin (using the method described in Chapter 3), we found greatly enhanced 
binding of the 22E7 mAb even though the subjects had negligible surface 
expression of FcRI on their eosinophils (unpublished data).
In an attempt to address these questions a further study was set up by our group. I did 
the preliminary work leading up to the study and helped devise the study protocol but 
the main study was taken on and completed by Dr Susan Smith, a Post-doctoral 
Fellow in the Department (Smith et al. 2000). In this study eosinophils were purified 
from the peripheral blood of six atopic subjects. Baseline FcRI expression was 
assessed by flow cytometry as described in section 2.1. Intracellular expression of 
FcRI was also analysed by flow cytometry after the cell membrane was made 78
permeable with saponin. The cells were then cultured for 20 hours with a variety of 
factors that may possibly cause upregulation of eosinophil FcRI surface expression 
in the microenvironment associated with allergic inflammation (IL-3, IL-4, IL-5, GM-
CSF, fibronectin, tissue fibroblasts, IgE). As well as assessment by flow cytometry, 
cytospins were prepared pre- and post culture for subsequent analyses by in situ 
hybridisation (evaluating the expression of mRNA for each of the three FcRI
subunits) as well as immunocytochemistry. 
Once again the blood eosinophils demonstrated negligible surface FcRI expression, 
smf (median and range) of 0.11 (0.10 – 0.12), thus confirming our previous 
observations, but after membrane permeabilisation there was increased 22E7 binding, 
smf 0.81 (0.41 – 1.0). This finding of increased expression of intracellular FcRI
was also seen in cytospin preparations. None of the culture conditions resulted in 
increased surface expression of FcRI; nor did any of the conditions result in 
significant increases in mRNA expression for any of the three FcRI chains (,  or ) 
– except for co-culture with fibroblasts resulting in a small but significant increase in 
FcRI mRNA (with no corresponding increase in the protein product). This study 
also tried to assess whether, even though the number of surface receptors detected 
were negligible in comparison to other cell types, they might have a functional role. It 
attempted to do this by evaluating whether there was any release of the eosinophil 
granule protein eosinophil peroxidase (EPO) resulting from crosslinking of receptors 
by an anti-FcRI mAb. There was no appreciable release of EPO resulting from 
cross-linking of FcRI. 
The conclusions to this study were therefore that blood eosinophils express very low, 
(in fact, in comparison to basophils, almost negligible), numbers of cell surface FcRI
and that these receptors appear to be non-functional. Surface expression was not 
inducible by any of the culture conditions studied but there was evidence of a sizeable 
intracellular pool of preformed FcRI in eosinophils. Furthermore a large proportion 
of eosinophils appear to express mRNA for all three subunits of the FcRI.
There have been three other studies published which have also attempted to try and 
answer some of these three questions (Seminario et al. 1999;Kita et al. 1999;Kayaba 79
et al. 2001). In a study performed by Seminario et al blood eosinophils were obtained 
from a variety of donors (normal controls, patients with asthma, allergic rhinitis or 
both and patients with a variety of hypereosinophilic disorders) were cultured for up 
to 11 days in the presence or absence of IgE and/or IL-4 (Seminario et al. 1999). The 
main findings of this study were similar to those of the Smith study – that is, no 
significant expression of surface FcRI on eosinophils was observed at baseline or 
after culture. However there was evidence of a significant quantity of intracellular 
FcRI chains, and also FcRI chains (but not -chains). In contrast to their lack of 
surface -chain expression, eosinophils did show surface expression of the -chain. 
Another interesting observation made in this study was that the supernatant of the 
cultured eosinophils did contain soluble FcRI chains. This indicated that the 
intracellular store of FcRI chains is available for release but for reasons that are 
unclear (certainly not apparently due to the lack of ‘stabilising’ -chains) very few, if 
any, -chains get expressed on the cell surface. 
The study by Kita et al (Kita et al. 1999) recognised that if eosinophils in the blood of 
atopic subjects express any FcRI at all, the numbers are so few that even a 
sophisticated and sensitive technology like multi-colour flow cytometry may not be 
sufficient to detect them reliably. Therefore they used a different approach to try and 
detect and quantify them. They purified blood eosinophils from subjects with ragweed 
sensitive hayfever obtained at the peak of the hayfever season and, as usual, found no 
significant expression of surface FcRI by flow cytometry. However they then 
cultured these cells with a chimeric IgE (cIgE) and confirmed that there was binding 
of cIgE to the cell surface. Since binding could be due to either (or both) high and low 
affinity Fc receptors (FcRI and FcRII) they looked at the impact of pre-treating the 
eosinophils with a saturating concentration of 15-1 (which of course is a competitive 
anti-FcRI mAb which would be expected to prevent IgE binding to the FcRI
chain). Interestingly 15-1 did partially inhibit cIgE binding, suggesting that there was 
indeed FcRI binding of IgE on these eosinophils. By quantifying the amount of 15-1 
inihibitable cIgE binding on eosinophils in comparison to that on basophils and 
monocytes from the same subjects, the investigators were able to estimate the relative 
levels of FcRI expression on these three cell types. The results were of a similar 
order of magnitude as in our study (section 2.1) – basophils FcRI expression was 80
some 125 times greater than monocytes and over 200 times more than eosinophils. 
However this study too was unable to detect any functional responses attributable to 
FcRI on eosinophils – they found no IgE dependant degranulation or release of 
leukotriene C4 or superoxide anion.
The final study was performed by the group that had originally described the presence 
of FcRI in eosinophils from hypereosinophilic patients. Once again they 
concentrated mainly on subjects with hypereosinophilia or haematological 
malignancies, with only 6 normal and 5 atopic individuals in the group of 30 subjects 
(Kayaba et al. 2001). Nevertheless it is worth briefly summarising their findings. 
They applied a quantitative flow cytometric method to measure the expression of 
FcRI both on the cell surface and intracellularly. In this group of subjects as a 
whole they found that there were on average around 4500 FcRI chains per cell 
expressed on the surface (as a comparison, basophils from atopic subjects could be 
expected to express ≥ 200000 receptors per cell) but almost 50000 FcRI chains per 
eosinophil intracellularly. In this slightly atypical group of subjects there was, for the 
first time, a correlation noted between surface receptor of FcRI on eosinophils and 
serum IgE concentrations. Their most interesting finding was that crosslinking of 
receptors with a murine anti-FcRI IgG mAb (15-1) together with the addition of an 
anti- mouse IgG polyclonal antibody resulted in the release of the cytokine IL-10. 
This therefore is the only study to have reported a functional response possibly 
attributable to FcRI stimulation on eosinophils.
In summary therefore, a number of studies have confirmed our observation that if 
blood eosinophils express high affinity IgE Fc receptors at all, the level of expression 
is very low – probably no more than a couple of thousand per cell in atopic subjects. 
Furthermore it does not appear that surface receptor expression is inducible in tissues. 
However several studies have shown that eosinophils may have a sizeable 
intracellular store of preformed FcRI chains and it appears that these are releasable 
under certain circumstances. The significance of this observation is still unclear. 
Finally, there still remains uncertainty as to whether the few surface receptors that are 
present on eosinophils in atopic subjects have functional significance. 81
6.3 Basophils and Interleukin-4
Basophils comprise less than 1% of circulating leucocytes in humans. Although they 
were first described by Ehrlich over a century and a quarter ago, until recently they 
were considered to have little significance in immune responses (unlike their close 
cousins, mast cells and eosinophils). A major reason for this was that no basophil-
specific markers had as yet been identified (and therefore there were no monoclonal 
antibodies, mAbs, with basophil specificity). This made it difficult to reliably identify 
basophils in blood or tissue and therefore greatly hindered research into their potential 
immunomodulatory roles.
It was only about a decade ago that researchers began to develop the specific tools 
necessary to take forward research into basophils and allergic inflammation. 
Technological advances included the development of highly sensitive fluorescence-
activated flow cytometers and cell sorters with multi-colour detectors which allowed 
rapid purification of even small numbers of particles. This was the technology used in 
our study, described in Chapter 3, which made use of their unique phenotypic 
properties to positively identify circulating basophils and was one of the first to 
describe that basophils do have intracellular stores of the cytokine IL-4 which could 
potentially be rapidly released (Kon, Sihra et al.1998).
Further significant developments in subsequent years have included the availability, at 
last, of basophil specific mAbs. Two in particular, BB1 (a mAb which binds to 
basogranulin, a basophil granule specific component) and 2D7 (which also recognises 
a basophil granule protein), have enabled researchers to finally identify basophils in 
tissues at sites of allergen induced inflammation. 
By using one of these mAbs to identify them in skin and bronchial biopsies following 
allergen induced late phase reactions, it was found that there is indeed an influx of 
basophils to these sites (Ying et al. 1999;Macfarlane et al. 2000;Nouri-Aria et al. 
2001). In fact there appears to be almost a thirty-fold increase in basophil numbers at 
the site of cutaneous late phase reactions and an eight-fold increase in bronchial 
biopsies (Macfarlane et al. 2000;Nouri-Aria et al. 2001). Furthermore it was 
confirmed that, at least at sites of allergen induced asthma, basophils do store IL-4 82
protein – with 40% of the basophils identified staining positively for intracellular IL-4
(Nouri-Aria et al. 2001). Indeed, although the number of basophils in bronchial 
biopsies is still relatively low compared to eosinophils and mast cells (Macfarlane, et 
al. 2000), they are major sources of IL-4 (almost 20% of IL-4 mRNA positive cells 
after allergen challenge were basophils) (Nouri-Aria et al. 2001).
A significant difference between basophils and mast cells appears to be the repertoire 
of cytokines they can secrete. Whereas mast cells have been shown to have the ability 
to synthesise and secrete an extensive array of pro-inflammatory cytokines (such as 
IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, GM-CSF, IFN-, TNF- etc), basophils appear to 
be more specialised – only producing IL-4 and IL-13. However these cytokines are 
released in quite large quantities following IgE-dependant stimulation (Arock et al. 
1993;Brunner et al. 1993;MacGlashan et al. 1994;Ochensberger et al. 1995;Gibbs et 
al. 1996;Li et al 1996) and, as has already been described, basophils appear to be 
major sources of IL-4 at sites of allergic inflammation. Furthermore, despite their 
relatively small numbers in blood, basophils were also found to be the predominant 
source of these two cytokines when peripheral blood mononuclear cells were 
stimulated by allergen in vitro (Devouassoux et al. 1999). The kinetics of the 
secretion from basophils are also important – as discussed in Chapter 3, preformed IL-
4 has been shown to be rapidly released from basophils stimulated by anti-IgE 
antibodies and the time course for IL-13 secretion is also quite rapid (Gibbs et al.
1996). 
The importance of the observations that basophils infiltrate sites of allergen-induced 
inflammation and are able to rapidly secrete these two particular cytokines (IL-4 and 
IL-13) has greatly changed the previous perception of them as having a rather limited 
role in allergy (perhaps just involved in immediate hypersensitivity) to possibly 
having important specialised roles in initiating and maintaining inflammatory 
responses. Both these cytokines are particularly significant as they work 
synergistically to help facilitate the influx of leucocytes (including eosinophils and 
basophils themselves). For instance, both promote upregulation of the adhesion 
molecule VCAM-1 on endothelial cells and are also potent inducers of the synthesis 
of the chemokine eotaxin by airway smooth muscle cells (Hirst et al. 2002;Moore et 83
al. 2002). Eotaxin is now considered to play a major role in the selective recruitment 
into lung tissue of eosinophils and basophils (both cell types express CCR3, the 
receptor for eotaxin) (Uguccioni et al. 1997;Ying et al. 1997;Conroy & Williams 
2001). Basophil derived IL-4 and IL-13 may also play important roles in isotype 
switching of immunoglobulin synthesis to IgE (and IgG4), as has been demonstrated 
in an elegant experiment (Yanagihara et al. 1998) in which it was shown that IgE 
stimulated cultured basophils promoted B-lymphocyte proliferation and induced
synthesis of IgE and IgG4 in vitro but these actions could be completely abrogated by
the addition of neutralising mAbs to IL-4 and IL-13 to the culture. IL-4 is also 
particularly influential as it induces the development of the TH2 phenotype of CD4+ 
T-lymphocytes – and the TH2 pattern of regulatory cytokines (including IL-3, IL-4, 
IL-5 and IL-13) is particularly associated with the atopy (Abbas et al. 1996).
Despite in vitro data such as those discussed above supporting the hypothesis that 
basophils may have an important role in allergen induced TH2 differentiation, in vivo
confirmation has proved elusive until very recently (Min & Paul 2008). In a murine 
model, Sokol et al found that not only did the protease allergen papain directly 
stimulate basophils but, most notably, resulted in them being recruited to local lymph 
nodes where they secreted IL-4 as well as another TH2 inducing cytokine TSLP 
(thymic stromal lymphopoetin) resulting in the differentiation of naive T-cells to TH2
cells. Moreover they also observed that pre-treatment with an FcRI specific 
antibody that caused profound basophil depletion resulted in papain induced TH2
responses being completely abolished – thus confirming the vital role that basophils 
play at least in protease allergen induced TH2 responses in this model (Sokol et al. 
2008).
One method of assessing the relative importance of the contribution of a pleiotropic 
cell to the processes of initiating and maintaining allergen induced inflammation is to 
assess the effectiveness of pharmacological agents that affect the cell’s functions at 
inhibiting allergen provoked early and late phase reactions (EPR and LPR 
respectively). The mechanisms of such reactions (involving target organs such as the 
skin, nose or lungs) have been well characterised over the years. The EPR is believed 
to result primarily from the rapid release of preformed histamine and newly generated 84
lipid mediators such as cysteinyl leukotrienes and prostanoids from IgE sensitised 
mast cells and basophils (Casale et al. 1987;Liu et al. 1991). In contrast, the LPR 
involves a characteristic inflammatory response that includes increased T-lymphocyte 
activation, local eosinophil (and basophil) accumulation and increased production of 
TH2 type cytokines (Bentley et al. 1997). 
When the studies contributing to this dissertation were performed, there were no 
agents available that had been shown to inhibit basophil function specifically. 
However the immunosuppressive drug cyclosporin A had been shown to be effective 
in patients with chronic, severe corticosteroid dependant asthma (Alexander et al. 
1992;Lock et al. 1996). CsA was initially thought to act primarily by inhibiting T-
lymphocyte function, but a number of studies had shown that it has a greater array of 
actions, including effective inhibition in vitro of IgE mediated exocytosis from 
basophils and mast cells (and subsequently it has also been shown to inhibit IL-4 and 
IL-13 synthesis in basophils) (Triggiani et al. 1989;Casolaro et al. 1993;Patella et al. 
1998;Genovese et al. 2003). In the study described in Chapter 4, the effects of CsA on
allergen provoked early and late asthmatic reactions were assessed and discussed. The 
discussion in Section 6.4 focuses on the contributions made both by our study and an 
ensuing one that also evaluated the effects of CsA on allergen induced asthmatic 
reactions to increased understanding of the roles that basophils as well as eosinophils 
play in these reactions. 
6.4 The Effects Of Cyclosporin A On Allergen-Induced Early And Late 
Phase Asthmatic Reactions
The main findings of the double blind, placebo controlled cross-over study described 
in Chapter 4 (Sihra et al. 1997b) were that cyclosporin A (CsA) significantly 
attenuated the late phase allergen induced asthmatic reaction and the associated 
increase in blood eosinophil counts but had no discernable effect on the early phase 
asthmatic reaction (which, as discussed above, is thought to be due mainly to allergen 
induced degranulation and release of mediators, such as histamine and cysteinyl 
leukotrienes, from IgE bearing mast cells and basophils in the airways). 85
Following the completion of the study in Chapter 4, there has been one further study 
of CsA and allergen induced asthmatic reactions. That study by Khan et al, published 
in 2000, was once again a double blind, placebo controlled randomised study 
involving pre-dosing of subjects with one dose of CSA or placebo before allergen 
challenge. However there were two differences in study design – it was a parallel 
group rather than a cross-over trial and on this occasion the subjects underwent 
bronchoscopies 24 hours before and after their allergen challenges (Khan et al. 2000). 
The aims of this second study were, firstly, to assess whether the observations of our 
study of the differential effects of CsA on early and late phase asthmatic reactions 
were reproducible but, more particularly, to determine whether CsA does have the 
inhibitory effects on eosinophil influx and eosinophil-active cytokines in the bronchi 
that were predicted in our study. A further aspect of this study was the availability of 
the basophil specific monoclonal antibody BB1. This allowed assessment of the 
possible impact of CsA on basophil influx as well.
The results were interesting. Once again the late, but not the early, asthmatic reaction 
was significantly attenuated by CsA (confirming that CsA does not have a major 
impact on allergen induced, FcRI mediated rapid degranulation of airway associated 
mast cells and basophils). CsA also significantly inhibited allergen induced increases 
in the number of activated eosinophils and cells secreting eotaxin in bronchial 
biopsies. Furthermore CsA also significantly inhibited allergen induced increases in 
cells expressing mRNA for the eosinophil-active cytokines IL-5 and GM-CSF studied 
in bronchoalveolar lavage fluid. Somewhat counterintuitively however, CsA did not 
have any significant impact on the allergen induced increases of basophils observed in 
the bronchial mucosa.
The authors’ conclusions were very similar to the conclusions of our original study –
that the attenuation of the late asthmatic reaction by CsA appears to be related to its 
inhibitory effects on synthesis of eosinophil-active cytokines and chemokines. 
However they did not really discuss the unexpected lack of impact of CsA on basophil 
influx. Basophils and eosinophils both express large numbers of the eotaxin receptor 
CCR3 and eotaxin is a strong chemoattractant for basophils, as it is for eosinophils 86
(Uguccioni et al. 1997;Iikura et al. 2001). Furthermore other chemokines that are 
involved in eosinophil chemotaxis, including RANTES and MCP-4 (acting via the 
receptor CCR3) also act on basophils (Uguccioni et al. 1997). Therefore it would be 
expected that the CsA associated effects on eotaxin and eosinophil influx would be 
mirrored by a similar impact on basophil influx.   
A clue may perhaps be obtained from observations of the kinetics of cell recruitment 
to the sites of allergen induced late phase reactions in the skin. As the skin is more 
readily accessible than the bronchi, it is feasible to perform biopsies at more frequent 
time points than in the lung. In one such study of kinetics (Macfarlane et al. 2000) it 
was observed that whilst eosinophil influx was relatively rapid (peaking by six hours 
after allergen challenge), basophil influx was slower (peaking by twenty four hours
after challenge). It seems probable that a similar difference in the rate of infiltration of 
basophils and eosinophils to the lung might be observed after allergen challenge if it 
were possible to take samples at additional time points.
There could be several possible explanations for a difference in the kinetics of 
infiltration:
 Whilst both cell types respond to chemokines acting through the CCR3 receptors 
(eotaxin, RANTES, MCP-4), these chemokines could act differentially (or have a 
different sequence of actions) on these two different cell types. There is in vitro
data from at least one study that may support such a hypothesis (Heinemann et al. 
2000).
 There may be other basophil specific chemokines or modulator factors (such as 
other cytokines). Basophils express five other types of transmembrane chemokine 
receptors besides CCR3 (CCR1, CCR2, CXCR1, CXCR2, CXCR4) and therefore 
do have the potential to respond to other chemokines – for instance IL-8 and MCP-
1, which act via CXCR1 and CCR2 respectively can induce migration of basophils 
in vitro (but they do not exhibit the same degree of potency as eotaxin) (Iikura et 
al. 2001). More promisingly, insulin-like growth factors-1 and -2 (IGF-1, IGF-2) 
have been shown to show selective basophil chemotaxis and enhance the 
chemotactic effects of eotaxin (Hartnell et al. 2004).87
 The presence of blood-derived granulocytes in tissues is a dynamic process 
dependant on the rate of influx into the target organ and survival of the cells when 
they are in the extravascular micro-environment. Biopsies at any time point do, of 
course, represent just a snapshot of these dynamic processes. Relatively little is 
known about the lifespan of basophils in tissues, with estimates varying from a few 
hours to a few days. A recent study found that in vitro, almost 60% of purified 
basophils underwent apoptosis by twenty four hours but that co-culture with IL-3 
significantly prolonged basophil survival (Zheng et al. 2002). This finding was 
consistent with a previous report that IL-3 is the main cytokine promoting basophil 
survival with other cytokines such as GM-CSF having relatively little efficacy 
(Yamaguchi et al. 1992). This of course contrasts with eosinophils where IL-3, IL-
5 and GM-CSF all enhance survival.
Whilst the study by Khan et al evaluated the effect of CsA on IL-5 and GM-CSF, it 
did not report on its impact, if any, on IL-3 synthesis nor did it look at its effects on 
chemotactic factors other than eotaxin which may regulate basophil trafficking. 
Moreover there did not appear to have been any evaluation of possible effects of CsA 
on basophil activation (e.g. analysis of CD69 expression). Taking all these variables 
into consideration the apparent dichotomous effects of CsA on eosinophil and 
basophil numbers in bronchial biopsies taken twenty four hours after allergen 
challenge may no longer appear to be quite so paradoxical.
Furthermore whilst the Khan study confirmed our observation of the lack of any 
significant impact of CsA on basophil or mast cell exocytosis (which is a relatively 
‘upstream’ events in signal transduction, as discussed in Section 1.5.3), the study did 
not look at its impact on IL-4 or IL-13 production. As discussed in Chapter 3 and in 
Section 6.3, basophils appear to be prominent sources of both IL-4 and IL-13, 
cytokines that may make significant contributions to the initiation and maintenance of 
IgE dependant allergen induced late phase allergic reactions. It is possible, given the 
known effects of CsA on downstream signalling events, that even though CsA does 
not appear to have any effect on basophil influx, it may still impact on their function 
by inhibiting cytokine synthesis.  In fact, although there have not been any published 
studies investigating possible effect of CsA on allergen induced basophil cytokine 88
production, effective in vitro inhibition of IgE/FcRI mediated basophil cytokine 
synthesis by CsA has been demonstrated by at least two studies. In the first study, 
CsA inhibited endogenous superantigen induced IL-4 release from basophils (Patella 
et al. 1998) and in the second it inhibited IL-4 and IL-13 secretion from basophils 
stimulated by a bacterial superantigen (Genovese et al. 2003). Both these 
superantigens were shown to act on basophils by crosslinking FcRI bound IgE. 
In conclusion, both studies looking at the effects of CsA on allergen induced reactions 
have demonstrated that CsA is effective in inhibiting the late asthmatic reaction but 
not the early asthmatic reaction (which is associated with exocytosis of preformed 
mediators such as histamine from FcRI bearing cells such as mast cells and 
basophils). Data from our study suggested that the effective inhibition of the late 
response may be due to inhibitory effects of CsA on eosinophil-active cytokines such 
as IL-5 and GM-CSF. The subsequent study appeared to support this hypothesis with 
significant impact on activated eosinophils in bronchial mucosa as well as IL-5 and 
GM-CSF. Interestingly CsA did not appear to have any impact on the increase in 
bronchial basophils observed twenty four hours after challenge. Whilst initially this 
may appear to indicate that basophils do not play a significant role in late asthmatic 
reactions, from the above discussion it is clear that there are still a lot of unanswered 
questions – and that as well as its effects on eosinophil influx and activation, the 
possible inhibitory effects of CsA on cytokine synthesis in basophils may quite 
conceivably make a significant contribution to its efficacy.
6.5 Prolonged Grass Pollen Immunotherapy And FcRI Expression On 
Peripheral Blood Cells
The efficacy of allergen specific injection immunotherapy (IT) in selected patients 
with seasonal allergic rhinitis is by now well established and many of the underlying 
mechanisms are quite well understood (Durham & Till 1998;Till et al. 2004). The 
study described in Chapter 5 (Durham et al. 1999;Sihra et al. 2000) was unusual in 
that it compared two groups of subjects who had successfully achieved symptomatic 
remission after prolonged grass pollen immunotherapy (up to four years) and then, in 
a double blind fashion, assessed whether the remission was sustained up to three years 
later, whether or not the subjects continued with active or placebo injections. 89
It has already been reported that subjects participating in this study did indeed 
maintain their clinical improvements and decreased magnitudes of the allergen-
induced cutaneous late (but not early) phase reactions to Timothy grass pollen 
(Phleum pratense) for at least three years after prolonged IT had been withdrawn 
(with no significant differences between the patients who continued to receive 
immunotherapy, the ITA group, and those who did not, the ITP group) (Durham et al.
1999). Of interest however were changes observed in various immunological markers 
in peripheral blood. Consideration of the patterns of these changes could have helped
elucidate if any the changes associated with active immunotherapy remain relevant to 
the prolonged efficacy of immunotherapy even after it is discontinued.
Whereas total circulating IgE concentrations remained unaltered for the duration of 
the study, immunotherapy was associated with significant changes in allergen specific 
immunoglobulins - IgE levels were reduced and IgG levels became elevated. These 
changes were apparent both in and out of the pollen season, with no seasonal 
variations observed. However, although these alterations were maintained in the 
group continuing to receive immunotherapy (ITA), withdrawal of immunotherapy in 
the ITP group of subjects was associated with allergen specific immunoglobulin 
concentrations tending to return towards pre-treatment levels in spite of their 
sustained clinical improvement.
Although pre-immunotherapy data on cellular surface expression of IgE receptors or 
serum concentrations of the soluble portion of the -chain of the high affinity IgE 
receptor (sFcRI) were unavailable, we were able to compare both immunotherapy 
groups (ITA and ITP) as well as 2 control groups (untreated rhinitics and non-atopic 
controls) at the end of the study. It was notable that at the conclusion of the study the 
surface expression of high affinity IgE receptors on both basophils and monocytes and 
also low affinity receptors on B-lymphocytes was similar in each of the three atopic 
groups irrespective of whether or not they had received immunotherapy. Furthermore 
although sFcRI levels measured in the final study year appeared to be significantly 
elevated during the pollen season (compared to pre-season values) in the ITA group, 
sFcRI levels did not significantly vary between the three atopic groups (ITA, ITP 90
and atopic controls).
The relevance of changes in specific immunoglobulins observed during IT has long 
been debated (Flicker & Valenta 2003). The ‘blocking antibody’ hypothesis suggests 
that elevated levels of allergen-specific IgG antibodies sequester allergen, preventing 
cross-linking of cell surface bound allergen-specific IgE and preventing IgE 
dependent cellular effector actions (van Neerven et al. 2006). Certainly there is in 
vitro evidence suggesting IgG blocking activity can prevent mediator release (van Ree 
& Aalberse 1995) and some studies have observed an association between specific 
IgG levels and clinical response to IT (McHugh et al. 1990). Certainly the initiation of 
allergen specific immunotherapy is associated with elevated serum concentrations of 
allergen specific IgG antibodies (Gehlhar et al. 1999;Till et al. 2004). However the 
results of the present study indicate that clinical improvements were maintained after 
withdrawal of prolonged IT even though specific IgE and IgG levels returned to pre-
treatment values in the group of subjects receiving the placebo treatment (although 
they continued to remain significantly altered in those subjects continuing to receive 
active immunotherapy). This could possibly indicate that changes in specific 
immunoglobulins observed after prolonged IT may just be ‘bystander phenomena’, 
reflecting altered immunoglobulin isotype switching responses, and are not directly 
relevant to sustaining the clinical benefit of IT after it has been withdrawn. Another 
possible explanation is that measurement of serum levels is a rather crude way of 
the blocking activity of allergen specific IgG, particularly of the IgG4 subclass 
(Nouri-Aria et al. 2004), may provide more clinically relevant data (Larche et al. 
2006).
The low affinity Fc receptor for IgE (FcRII or CD23) is a C-type lectin that binds 
IgE with a lower affinity than FcRI (Bonnefoy et al. 1993a). CD23 molecules 
expressed on B-lymphocytes appear to have several functions which may be 
important in the IgE mediated inflammatory cascade (summarised in Section 1.6). IL-
4 of course plays an important role in the preferential up-regulation of CD23 
expression on B-lymphocytes (a role that is significantly inhibited by IFN-)
(Bonnefoy et al. 1993a; Lee et al. 1993).
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It may be surmised therefore that effective allergen immunotherapy would result in 
reduced expression of CD23 on B-lymphocytes. Indeed, significant reductions in both 
the percentage of CD23 expressing B-cells and receptor density have been observed 
in a group of asthmatic subjects who received rush immunotherapy with 
Dermatophagoides pteronyssinus, (Kljaic-Turkalj et al. 1996). However the results of 
our study did not show any significant reductions in CD23 expression after prolonged 
IT. One possible reason could be that the freshly isolated B-cells were analysed in a 
resting state as they were studied at the end of the pollen season and it is possible that 
the findings might have been different had these B-lymphocytes obtained from these 
subjects who had undergone prolonged immunotherapy been co-cultured in vitro with 
grass pollen (Phleum pratense). Indeed reduced expression of CD23 on allergen-
stimulated cultured peripheral blood B cells following immunotherapy has been 
reported in at least one study (Jung et al. 1995). 
As has already been discussed in the papers comprising Chapters 1 and 2, high 
affinity Fc receptors for IgE (FcRI) are expressed not just on basophils and mast 
cells but also on other effector cells - including blood monocytes, on which FcRI
expression is up-regulated in atopics (Maurer et al 1994;Sihra et al 1997a), and 
monocytes-derived dendritic cells (Maurer et al. 1996). Furthermore, as described in 
Section 5.2, FcRI on such antigen presenting cells (APC) appear to lack the 
subunit (Bieber 1996)and are therefore expressed as trimeric complexes in contrast to 
classical FcRI expressed on cells containing preformed mediators (mast cells, 
basophils and even eosinophils), which are tetrameric complexes.
Immunotherapy could potentially exert several immunomodulatory effects through 
actions on FcRI expressing cells. As has already been discussed, both mast cells and 
basophils have been shown to be sources of TH2-type cytokines (particularly IL-4) 
which can be rapidly released following IgE-dependent stimulation (Bradding 
1996;Gibbs et al. 1996). Thus these cells may not just have roles limited to the 
allergen induced early phase reaction (EPR) but may also be involved in initiating the 
inflammatory changes associated with late phase reactions (LPR). The critical role of 
IL-4 in promoting IgE isotype switching has been discussed above. Effective 92
immunotherapy is associated with reduced IgE-dependent basophil releasability of 
preformed mediators (Malling et al. 1982). Suggested mechanisms for this include 
either reduced FcRI surface expression or functional impairments of these receptors 
(Kimura et al. 1985). Although no study has as yet specifically assessed this, it is also 
Potentially of even greater significance is the expression of FcRI on professional 
APC such as monocytes. The presence of allergen-specific IgE on these receptors 
‘focuses’ allergen presentation to T-lymphocytes (similar to the role of IgE/FcRII on 
B-cells). Such FcRI dependent allergen focusing has been shown to increase the 
effectiveness of antigen presentation by monocytes by up to 1000-fold in vitro 
(Maurer et al. 1995). It is possible that enhanced allergen presentation is important 
particularly at the initiation of immunotherapy as elevated allergen concentrations 
may promote the TH1 phenotype (Hosken et al. 1995) and in fact have been shown to 
significantly reduce in vitro IL-4 production by CD4+ T-cells, particularly when
allergen is presented by monocytes (Secrist et al. 1995). However it is also feasible 
that prolonged IT could induce decreased IgE-dependent allergen trapping by APC 
and therefore less efficient antigen presentation to T-cells - reflected in vitro by 
reduced allergen-specific proliferative responses (Baskar et al. 1997;Ebner et al. 
1997). As well as possibly regulating the functions of cell membrane FcRI, IT could 
conceivably act by actually down-regulating surface expression of these receptors 
both on granular cells and on monocytes, as IL-4 has been shown in vitro to up-
regulate FcRI expression on mast cells (Toru et al. 1996) and monocytes (Reischl et 
al. 1997).
However in the present study we were unable to demonstrate significant reductions in 
surface FcRl expression on blood basophils or monocytes following IT. In retrospect 
this should perhaps not be surprising, since we now know that FcRI expression on 
these cell types in vivo appears to be related predominantly to serum total IgE 
concentrations (Sihra et al. 1997a), and these were not affected by IT. Indeed it was 
interesting that there was still a significant positive correlation between basophil 
FcRI expression and circulating total (but not specific) IgE concentrations after IT in 
our study group. It would certainly be of interest to evaluate the amount of allergen 
likely that basophil cytokine releasability is significantly impaired by IT.93
specific IgE actually bound to these receptors as well as the IgE-dependent allergen 
presenting capacity of monocytes from IT treated subjects.
A soluble form of the  chain of FcR1 (sFcRI) that appears to be stored in, and 
released, from the granules of basophils and eosinophils and retains the high affinity 
IgE binding capability of membrane-bound IgE (Bjerke et al. 1994;Bjerke et al. 1997)
has been identified. Although its exact significance is unclear, an inhibitory role has 
been postulated for this molecule in IgE-mediated allergic inflammation. 
Recombinant sFcRl reportedly inhibited IL-4 and allergen-induced IgE production 
selectively in vitro (Bjerke et al. 1994;Yanagihara et al. 1994) –  possibly by binding 
to CD23-bound IgE on B-lymphocytes and thus blocking allergen binding. As 
sFcRl is monovalent, it is non-anaphylactogenic –  in fact the recombinant form 
appears to prevent mast cell degranulation in vivo (Naito et al. 1996). Thus sFcRI
could theoretically be another natural ‘blocking’ molecule in allergy. The mechanisms 
modulating sFcRI levels have still not been established. Therefore the observation 
in this study of a positive correlation to total IgE concentrations in IT treated patients 
(rather similar to that observed between basophil FcRI expression and total IgE) is 
intriguing. In the context of the mechanisms of IT, of more interest was the 
observation of elevated sFcRI levels during the pollen season in the group 
receiving active IT. This observation was somewhat counterbalanced overall by the 
lack of significant differences between the ITA and ITP groups. However it does 
suggest that further analyses of the role of this molecule, particularly during the early 
course of IT, would be merited.
In summary, the results of this study suggested that the clinical efficacy of 3-4 years 
of continued allergen injection immunotherapy may be sustained for at least a few 
years after cessation of treatment. However this was not reflected by significant 
quantitative changes in any of the blood parameters we looked at (humoral factors or 
IgE receptor expression on effector cells that may be involved in the initiation or 
inhibition of IgE-dependent allergic inflammation). Although initially appearing to be 
somewhat disappointing, these observations do nevertheless contribute to improving 
our understanding of immunotherapy. Of course changes in many of the parameters 
assessed have been observed during active immunotherapy in many studies and do 94
seem to some extent to correlate with clinical benefit in these (as described above and 
in the introductory section of Chapter 5). However this particular study was fairly 
unique as it evaluated subjects in whom active immunotherapy had ceased and found, 
for example, that changes in allergen specific serum IgE and IgG did not seem as 
important for sustained benefit as they may appear to be during initiation of IT. 
Of course blood derived IgE receptor bearing cells could still play a significant role in 
some of the processes involved in maintaining the efficacy of IT. For instance, were 
the study to be repeated today, it would be instructive to investigate functional 
changes in IgE / IgE-receptor allergen trapping mechanisms (e.g. changes in the 
proportion of receptor bound allergen specific IgE) and indeed effector actions further 
downstream which may be relevant (e.g. an in vitro comparative study of allergen 
induced lymphocyte proliferation with monocytes derived from subjects who had 
either continued or discontinued their IT). One further caveat to consider when 
assessing the effects of prolonged IT is that it is possible that changes in the local 
microenvironment at sites of allergic inflammation (e.g. the nasal mucosa) that may 
be relevant to its sustained efficacy may not necessarily be accurately reflected in 
peripheral blood.
Taken as a whole however, perhaps the most insightful analysis of the outcomes of
this study may be that all of them would be compatible with the hypothesis that the 
mechanism most relevant to the clinical benefit of prolonged IT persisting even after 
it has been discontinued may be the modification on T-lymphocyte responses to 
natural allergen exposure (Durham & Till 1998), either by causing an enduring shift
in the balance of predominant allergen-specific responses from TH2 toTH1 (Till 1997)
or by upregulating IL-10 producing adaptive regulatory T cells that are capable of 
suppressing TH2 type responses (van Oosterhout & Bloksma 2005). 
In fact, although IL-10 secretion was not specifically assessed in our particular study, 
in a subsequent study increased allergen induced IL-10 secretion from PBMC has 
been observed in subjects who had received 2 years of grass pollen IT (Nouri-Aria et 
al. 2004). This observation has been repeated in a very recent study, in which it was 
noted that increased IL-10 production was observed within a few weeks of the 
initiation of allergen specific IT and coincided in time with the inhibition of cutaneous 95
late phase reactions (Francis et al. 2008). In this respect, probably the most relevant
observations from the subjects involved in the study described in Section 5 were that 
not only did both groups (ITA and ITP) demonstrate persistent inhibition of cutaneous 
late phase responses to Phleum pratense, but also had significantly reduced numbers 
of CD3+ T-lymphocytes and cells containing mRNA for IL-4 at the sites of their 
intra-dermal allergen challenges (Durham et al. 1999). These findings, indicating a 
profound and sustained suppression of TH2 responses associated with prolonged IT, 
were therefore certainly consistent with the above hypothesis.
Although too vast a topic to discuss in any great depth in this thesis, the significant 
advances that have taken place over the last few years in beginning to understand the 
some of the complex mechanisms of how dendritic cells (many of which in atopic 
individuals express FcRI of course, as described in Section 6.2.2) promote regulatory 
T cell response are considered increasingly relevant to the efficacy of allergen specific 
IT (Larche et al. 2006;Akdis et al. 2006). Therefore a fairly brief synopsis of the most 
significant points is provided below.
6.6 Regulatory T-cells and Dendritic Cells: a synopsis of recent advances in 
understanding the roles of these cells in controlling immune responses
Until very recently DCs were thought of mainly as proficient antigen presenters –
somewhat akin to highly efficient ‘factory ships’ that detect and capture antigens then 
process, package and present them to lymphocytes. However it is now evident that 
DCs play at least an equal role to T-lymphocytes in deciding the nature of antigen 
specific responses. Indeed a more appropriate metaphor is that if lymphocytes are the 
‘generals’ that prosecute battles against pathogens, DCs are ‘strategic intelligence’ 
assessing potential pathogens and counselling T-lymphocytes whether to tolerate 
them or, if a specific immune response  is required, helping decide the nature of this 
response. Some recent advances in our knowledge of complex interactions between 
DCs and T-cells involved in these regulatory decision making processes are 
summarised in the following sections.96
6.6.1 Regulatory T-cells
The roles of different subsets of CD4+ T-cells in immunity are well established. In 
addition, the existence of putative suppressor T-lymphocytes that could limit harmful 
immune responses had been suspected for years but identification of such cells proved 
to be very difficult. This continued to be the case until a series of experiments in the 
mid-1990s demonstrated that the adoptive transfer of CD25+ depleted CD4+ T-cells 
into athymic nude mice resulted in multi-organ autoimmune diseases – which could 
however be prevented if reconstituted CD4+CD25+ cells were also inoculated shortly 
afterwards (Sakaguchi et al. 1995).  CD25, the -chain of the receptor for interleukin-
2, had until then thought to be expressed on activated effector T-cells but this was 
probably the first indication that some CD4+CD25+ could also be involved in down-
regulating immune responses. In the ensuing years a substantive body of evidence has 
accumulated confirming the presence of at least two distinct subsets of CD4+ T-cells 
in humans (as well as mouse models) that can inhibit or suppress T-cell activation and 
consequent harmful immunopathological responses to self or foreign antigens 
(Shevach 2000;Shevach 2002;Maloy & Powrie 2001;O'Garra & Vieira 2004). These 
inhibitory T-cells are termed regulatory T-cells (Treg cells).
A major impediment to the study and characterisation of Treg cells in humans has 
been the lack of a unique or specific cell surface marker allowing them to be 
identified easily (Romagnani 2006). Nevertheless it is now generally accepted that 
there are at least two main categories of Treg cells – natural Treg (nTreg) and 
adaptive Treg (aTreg) cells – that appear to be functionally and phenotypically 
distinct and develop at different anatomical sites (Bluestone & Abbas 2003). 
Natural Treg cells are predominantly generated in the thymus, following which they 
move on to blood and peripheral lymphoid tissues. These cells are present in all 
normal individuals where they are thought to represent between 5-10% of the CD4+ 
lymphocyte population (van Oosterhout & Bloksma 2005;O'Garra & Vieira 2004) and 
are mainly associated with the induction of tolerance to self antigens.  
Characteristically they express constitutively high levels of CD25 as well as the co-
inhibitory molecule (Chikuma & Bluestone 2003) CTLA-4 (cytototoxic T-97
lymphocyte antigen 4) and GITR (glucocorticoid induced tumour necrosis factor 
receptor), a member of the TNF superfamily (Bluestone & Abbas 2003). However, as 
has already been discussed, none of these markers are exclusive to nTeg cells. 
Perhaps the one relatively exclusive marker for nTreg cells is the transcription factor 
Foxp3 (Hori et al. 2003;O'Garra & Vieira 2003). The presence of Foxp3 seems to be 
essential for nTreg cell development (Fontenot et al. 2003) and mutations in the gene 
encoding for this transcription factor can result in immune dysregulation syndromes 
such a the X-linked autoimmune and allergic dysregulation syndrome as well as X-
linked neonatal diabetes, enteropathy and endocrinopathy syndrome (Romagnani 
2006). Until very recently therefore it was thought that the expression of Foxp3 was 
an essential early step for naive T-cells to become committed nTreg cells in the 
thymus – however, as all too often proved to be the case in the rapidly progressing 
study of regulatory mechanisms, the situation has proved to be far more complex than 
initially thought. For instance, it is possible that under certain circumstances Foxp3 
expressing regulatory T-cells could be generated from conventional CD4+ T-cells in 
the periphery – as several recent studies have reported that CD4+CD25– cells can 
upregulate Foxp3 after in vitro activation (Walker et al. 2003;Chen et al. 2003;Cong 
et al. 2005;Razmara et al. 2008).
In contrast to nTreg cells, adaptive Treg cells are generated in peripheral lymphoid 
tissue mainly in response to foreign antigens presented by tolerogenic  dendritic cells 
(which are discussed in greater detail in Section 6.6.4) to T-cells (Bluestone & Abbas 
2003;Hawrylowicz 2005). It is now generally accepted that there are at least two 
major subtypes of aTreg cells – termed TR1 and TH3 cells (Hawrylowicz 
2005;Romagnani 2006). Although both subtypes do express CD25, its expression is 
variable and does not appear to be constitutive as in nTreg cells. TR1 cells do not 
appear to express Foxp3 and this is also probably the case for the majority of TH3
cells (Romagnani 2006). It is also now generally accepted that the immunoregulatory 
actions of both aTreg subtypes are mediated by the secretion of specific inhibitory 
cytokines – TR1 cells produce IL-10 and TH3 cells secrete TGF-(Bluestone & Abbas 
2003;Romagnani 2006).98
6.6.2  Interleukin-10 (IL-10)
Although it was originally described as a TH1 inhibitory cytokine produced by TH2
cells (Fiorentino et al. 1989;Fiorentino et al. 1991)}, it very soon became apparent 
that IL-10 is also secreted by TH1 cells (Del Prete et al. 1993) as well as other cell 
types – particularly antigen presenting cells like monocytes (de Waal Malefyt et al. 
1991a;Parry et al. 1997) and dendritic cells (Akbari et al. 2001;Weigt et al. 2003;Qi et 
al. 2003) in certain circumstances. IL-10 has several immunosuppressive actions 
(Moore et al. 2001;Pestka et al. 2004), including many which may have relevance to
allergen specific immunotherapy (Jutel et al. 2006). These include:
 It inhibits proliferation of CD4+ T-lymphocytes by its actions on APCs 
(Fiorentino et al. 1991);
 It potently inhibits secretion of pro-inflammatory cytokines such as IL-1, IL-6, 
IL-12 (a particularly important cytokine for the generation of TH1 cells), GM-
CSF, TNF- and, in an autocrine manner, IL-10 itself, from cells of 
monocyte/macrophage lineage. Furthermore it also suppresses secretion of both 
CC and CXC chemokines from activated monocytes (Moore et al. 2001);
 It inhibits both the maturation of DCs from monocyte precursors (Buelens et al. 
1997) and their expression of MHC class II molecules and co-stimulatory 
molecules (de Waal Malefyt et al. 1991b;Moore, de Waal Malefyt et al. 2001). 
As will be discussed shortly, these may be important actions in the generation of
aTreg cells – including TR1 cells, which as described above, further produce IL-
10;
 It can also downregulate TH2 responses (Grunig et al. 1997). Particularly relevant 
to immunotherapy is the observation that IL-10 can induce PBMCs to 
differentially produce IgG4 in preference to IgE in vitro (Jeannin et al. 1998);
 It has been shown to inhibit IgE induced mast cell activation (Royer et al. 2001)
and also cytokine production from mast cells (Arock et al. 1996);
 IL-10 has been observed to reduce eosinophil survival, activation and cytokine 
production (Takanaski et al. 1994).99
6.6.3 Dendritic cells – arbitrators of tolerance or immunity
At almost the same time that the existence of two main Treg subsets was proposed 
(Bluestone & Abbas 2003), it became apparent that DCs also play a fundamental role 
in deciding whether the response to a pathogen should be tolerance or immunity 
(Buckland 2003). 
It was already known that DCs can help skew immune response toward a 
predominantly TH1 or TH2 pathway. For instance, DCs of myeloid lineage, producing 
the archetypical TH1 stimulating cytokine IL-12, had been shown to be efficient 
promoters TH1 cell development from naive CD4+ T-cells (Macatonia et al. 1995)
whereas pDCs could be shown to induce TH2 type responses (Iwasaki & Kelsall 
1999). Indeed mDCs and pDCs were at one stage designated DC1 and DC2 cells, 
based on their ability to promote TH1 or TH2 responses respectively (Kalinski et al. 
1999;Kapsenberg & Kalinski 1999;Kapsenberg et al. 1999;Moser & Murphy 2000).
However it very soon became apparent that the promotion of TH1 or TH2 type 
immunity is not an exclusive property of one or other of these two DC subsets 
(Schuurhuis et al. 2006). Furthermore it also became apparent that whilst DCs are 
efficient at promoting adaptive immune responses, they can be equally adept at
promoting tolerance through induction of pathogen specific Treg cells (Abbas & 
Sharpe 2005). Rapidly increasing knowledge of the sequence of events involved 
between pathogen recognition and capture by DCs and antigen presentation by them 
to naive T-cells has resulted in significantly better understanding of how and why 
DCs might promote either immunogenic or tolerogenic pathogen specific T-cell 
responses (Schuurhuis et al 2006).
6.6.4 Dendritic cells and the generation of adaptive regulatory T-cells
It was soon realised that the classification of DCs into DC1 and DC2 subsets was far 
too simplistic – in fact the DCs network is a very sophisticated one and DC subsets 
appear to demonstrate great functional flexibility to induce different T-cell responses 
taking into account factors such as the nature of the pathogen, the tissue type and 
microenvironment in which it is encountered, the dose of pathogen, the pattern 
recognition receptor used to detect it etc before ‘advising’ T-cells to adopt specific 100
immune or regulatory response phenotypes (Kapsenberg 2003). Some of the 
important factors that effect this decision making process include:
a. Tissue specific DC phenotype
As discussed in Section 6.2.2, DCs at different sites appear to have different 
phenotypes, even though broadly following into the categories of mDCs and pDCs 
(Novak et al. 2004). For instance the majority of oral and nasal DCs have a myeloid 
lineage but differ in expression of FcRI (expressed constitutively in both but with 
higher expression in oral DCs), co-stimulatory molecules (CD40 and CD80/CD86 
higher in nasal DCs) and MHC class II expression (higher in oral mDCs) (Allam et al.
2006). In turn, both oral and nasal DCs differ from classical skin Langerhans cells as 
well as IDEC (inflammatory dendritic epidermal cells), a type of mDC found 
specifically in inflamed skin in subjects with atopic dermatitis, both of can be can be 
induced to express FcRI in atopics and at  higher levels than in oral or nasal mucosa
(Bieber 2007). Interestingly oral mucosa DCs seem to be quite tolerogenic, and have a 
propensity to produce the suppressive cytokines IL-10 and TGF- (Novak et al.
2004;Bieber 2007). In contrast the skin DCs are more likely to be pro-inflammatory –
with classical LCs inducing TH2 mediated inflammation and IDECs promoting 
predominantly TH1 responses (Novak & Bieber 2005).
b. DC maturity
The majority of DCs in skin and mucosal tissues are of course relatively immature. 
Immature DCs are highly efficient at recognising, capturing and internalising antigens
(by phagocytosis or receptor mediated endocytosis) and processing them by 
proteolysis into peptide fragments that can eventually be presented to T-cells. 
Therefore immature DCs highly express pattern recognition receptors such as Toll 
like receptors (TLR), immunoglobulin Fc receptors (including FcR and FcRI) and 
C-type lectin receptors. However they have low expression of the co-stimulatory 
molecules (such as CD40, CD80 and CD86) and adhesion molecules. Although they 
express high intracellular levels of MHC class II molecules (residing in specialised 
endocytic compartments called MHC II enriched compartments or MIIC), surface 
MHC II expression is relatively low when compared to mature DCs (Schuurhuis et al.
2006). 101
If the conditions are right (particularly the absence of suppressive cytokines like IL-
10) DCs rapidly mature and migrate to local lymphoid organs where they can present 
the processed peptides to naive T-cells by MHC II molecules-T cell receptor/CD3 
complex interaction. The process of DC maturation involves a major metamorphosis 
into non-endocytic antigen presenting cells with changes in cell shape (development 
of numerous processes called dendrites), loss of the endocytic and phagocytic 
receptors, upregulation of adhesion molecules and chemokine receptors (e.g. CCR7) 
that facilitate the migration and greatly increased surface expression of MHC II and 
co-stimulatory molecules (including the three mentioned above) (Schuurhuis et al.
2006).
In general, it appears that mature DCs are efficient at initiating immunogenic T-cell 
responses whilst immature DCs promote tolerance (Abbas & Sharpe 2005). This was 
elegantly demonstrated in an experiment in which immature or mature human 
monocyte derived DCs were used to repetitively stimulate allogeneic naive CD4+ T-
cells. The T-cells stimulated by mature DCs differentiated into activated TH1 type 
cells whereas those repetitively stimulated by the immature DCs developed a Treg
phenotype (expressing CD25 and CTLA-4 and secreting IL-10) (Jonuleit et al. 2000). 
Intriguingly this in vitro mechanistic study suggested two separate ways DCs could
significantly contribute to the efficacy of allergen specific immunotherapy in vivo, by 
promoting either immune deviation or tolerance (or possibly both in the long term). 
c. Receptors involved in pathogen recognition and capture
Dendritic cells express a large variety of receptors that allow them to recognise, 
capture and internalise pathogens. Some, particularly receptors for the Fc domain of 
immunoglobulins, confer a degree of antigen specificity. The functional consequences
of ‘antigen focusing’ by FcRI on DCs, in particular, have already been discussed in 
this thesis. 
However DCs, unlike T-lymphocytes for instance, are not pathogen specific cells –
indeed they possess the vital ability to detect danger patterns on any number of 
pathogens and instruct the adaptive immune system on appropriate responses. DCs 102
possess a variety of pattern recognition receptors such as lectin, mannose and heat 
shock protein receptors but ones that have attracted most recent attention are the ten 
TLR (Toll like receptors). TLR of course mediate innate immunity  by recognising 
conserved microbial constituents (Beutler 2002) such as lipoproteins (TLR2-TLR1), 
peptidoglycans and zymosan (TLR2-TLR6), lipopolysaccharides, LPS (TLR4), viral 
dsRNA (TLR3) and bacterial DNA containing CpG motifs (TLR9 found on pDCs) 
(Schuurhuis et al 2006) but intracellular signals that result from the activation of at 
least some of them can also modify adaptive immune response (Abreu & Arditi 
2004). For instance, in vitro stimulation of mDCs by three different TLR activators 
LPS, peptidoglycan or zymosan induced different levels of inhibitory (IL-10) or pro-
inflammatory (IL-12) cytokines and resulted in generation of different T-cell 
phenotypes (Qi et al. 2003). Similarly, activation of oral mucosal Langerhans cells by 
a TLR4  agonist resulted in CD4+ T-cells showing upregulation of co-inhibitory 
molecules (B7-H1 and B7-H3), downregulation of the co-stimulatory molecule CD86 
and upregulation of Foxp3 and the inhibitory cytokines IL-10 and TGF-1 as well as 
the TH1 cytokine IFN- (Allam et al. 2008). 
The facility of these receptors of innate immunity on DCs to alter antigen specific T-
cell responses may be relevant to the allergic condition – for instance, in a very recent 
study it was observed that circulating pDCs from atopic individuals stimulated with 
the TLR9 specific ligand, CpG-DNA, have a greatly reduced propensity to produce
IFN- (the prototype TH1 cytokine) than those from non-atopic subjects despite the 
numbers of pDCs and TLR9 expression being similar in the two groups (Tversky et 
al. 2008). 
d. The role of co-stimulatory or co-inhibitory molecules
The antigen presenting interaction between MHC II molecules on APCs and T-cell 
TCR-CD3 complexes needs an additional non-antigen specific co-stimulatory second 
signal for activation to occur. This involves interaction between accessory signalling 
molecules on the presenting DC and the T-cell receiving the antigen. Recognised 
pairs of co-stimulatory molecules include CD40 and CD40 ligand, CD80 or CD86 
and CD28 on APCs and T-lymphocytes respectively. CD80 and CD86 on APCs can 
also interact with the co-inhibitory molecule CTLA-4 on T-cells and in fact have a 103
much higher affinity for this molecule than for CD28 (Abbas et al. 1996). It is 
generally thought that antigen presentation to T-cells without concomitant co-
stimulation (as is likely with immature DCs with their low levels of expression of co-
stimulatory molecules) results in T-cell anergy whereas efficient co-stimulation by 
mature DCs leads to effector response (Schwartz 2003). Recently it has been 
postulated that such a mechanism may cause temporary functional unresponsiveness 
but not necessarily anergy. Instead it has been postulated that, for instance, the 
relatively few numbers of CD80 or CD86 molecules expressed on immature DCs may 
still effectively bind co-inhibitory CTLA-4 molecules and, in the presence of 
inhibitory cytokines such as IL-10 and TGF- promote regulatory rather than effector 
T-cells (Abbas & Sharpe 2005). Although this still remains an attractive but unproven 
hypothesis, there seems little doubt that accessory signalling molecules are relevant to 
antigen specific tolerance inducing interactions between DCs and T-lymphocytes.       
e. Tissue factors
Whilst the contact interaction between DCs and T-cells involving ligation of TCRs by 
MHC class II molecules together with the engagement of the accessory signalling 
molecules (signals 1 and 2 respectively) is important in determining whether the T-
cells mount an effector response or not, the decisive factor as to the precise nature of 
the response (signal 3) is thought to be the local microenviroment where DCs 
encounter the pathogen (Kalinski et al. 1999). The presence or absence of many 
factors such as pro-inflammatory cytokines (e.g.IL-12 family members, IFN-, IL-10, 
TGF-, MCP-1), eicosanoids, heat shock proteins, extracellular matrix components 
etc can significantly alter DC activation and maturation and thus effect the nature of 
the DC modulated adaptive reponse to a particular antigen (Kapsenberg 2003).
6.6.5 Dendritic cells and immunotherapy: a brief summary of recent advances
Better understanding of the regulatory function of DCs and how all of the factors 
described above may effect this (Novak & Bieber 2008) has stimulated research on 
how to utilise DCs to enhance immunotherapy for conditions as diverse as cancers, 
autoimmune diseases, transplant medicine and, of course, allergen specific 
immunotherapy (Figdor et al. 2004). The basic concept is that antigens, or allergens,104
should be targeted to one or more specific type of receptors on DCs at particular 
anatomical sites to achieve the desired T-cell response (Tacken et al. 2007). 
In allergen specific immunotherapy the simplest application of this idea has been to 
try and exploit the constitutively high level of FcRI expression of DCs in the oral 
mucosa and, as discussed above, their essentially tolerogenic nature through 
sublingual allergen specific immunotherapy or SLIT (Akdis et al. 2006). One example 
of the success of this approach was demonstrated in a recent study in which patients 
who responded to birch pollen SLIT, an increased number of circulating TR1 cells 
with increased IL-10 but reduced IL-4 and IFN- expression was noted within four 
weeks of commencing SLIT. However after one year of SLIT, IL-10 secreting Treg 
cells were reduced but there was now evidence of allergen specific immune deviation 
to a predominantly TH1 response (increased IFN- but little IL-4 production) (Bohle et 
al. 2007).
A slightly more sophisticated approach involves conjugating the allergen to DC 
receptor ligands – particularly TLR stimulatory sequences. The theory is that if a 
particular type of TLR is stimulated at the same time as allergen is presented to a DC 
via FcRI bound IgE, the TLR ligand will act as an adjuvant and modulate the 
subsequent allergen specific T-cell response.  Such an approach has been recently 
been trialled using Amb a 1 (the ragweed pollen antigen) conjugated to a synthetic 
DNA sequence containing CpG motifs that is a TLR9 specific ligand (Marshall et al. 
2001;Tulic et al. 2004;Simons et al. 2004;Creticos et al. 2006). Two recent clinical 
studies of SCIT using this conjugate in ragweed sensitive rhinitics did demonstrate 
clinical efficacy and, as might have been anticipated, evidence of immune TH1
deviation (Tulic et al. 2004;Creticos et al. 2006). This ability of this allergen
conjugate to skew allergen specific cytokine responses from TH2 towards TH1 in vivo
was also demonstrated in another study involving ragweed allergic patients receiving 
a short subcutaneous course of the conjugate (Simons et al. 2004). A grass pollen and 
monophosphoryl lipid A conjugate, this time simultaneously targeting TLR4 and 
FcRI, has also shown similar promise (Mothes et al. 2003;Drachenberg et al. 2001)105
The development of immunotherapy strategies targeting DCs is a particularly fertile 
area of research, especially in cancer medicine (although the idea there is more to
‘switch on’ immunity rather than tolerance) (Tacken et al. 2007). However there is 
little doubt that these DC based vaccine strategies will also eventually be used in 
allergy. One approach that could, for instance, be effective would be to combine
allergen specific IT with strategies aimed at modulating co-stimulatory or co-
inhibitory molecules – such as a novel fusion protein, CTLA-4.Ig or abatacept, which 
is already available and has been shown, when combined with MHC II-TCR ligation 
in vitro, to convert naive CD4+ T-cells to CD4+CD25+ Treg cells (Razmara et al.
2008). Thus it appears likely that the presence of FcRI on DCs coupled with 
increasing knowledge of how to accurately and reliably manipulate DC functions will 
result in greater efficacy and safety of allergen specific immunotherapy in future.
6.7 Conclusion
Four decades have now passed since the discovery of IgE but it is only in the last ten 
to fifteen years that rapid and significant advances have been made in our knowledge 
of FcRI – the high affinity receptor for IgE. Fascinating insights have been gained 
not just into the structure of this receptor but also how the peculiar topology of the 
IgE binding site on the -chain of FcRI is fundamental to the extremely potent 
stability of the binding of IgE to this receptor. Our knowledge of events both in the 
cell membrane and intracellular signalling pathways has also advanced apace. 
However perhaps one of the most exciting developments, particularly with regard to 
our understanding of the cellular basis of IgE mediated allergic inflammation, has 
been the identification of a greatly increased repertoire of cells, both in blood and in 
tissue, that possess functional FcRI on their surfaces. These now include several 
types of antigen presenting cells (APCs), especially those of monocytes/macrophage 
lineage such as mDCs, on whom the surface expression, particularly in atopic 
subjects, appears to be inducible. As discussed above, the presence of strongly bound 
allergen specific IgE on the FcRI on these cells, may greatly enhance the ability of 
these cells to present allergen to T-lymphocytes (cells that are now considered to be 
particularly important pro-inflammatory and regulatory cells in allergic 106
inflammation). Furthermore, the advances in knowledge mean that even the cell types 
that have long been known to constitutively express large numbers of surface FcRI, 
mast cells and basophils, are now considered to have broader roles in allergic 
inflammation than just being fundamental in Type I IgE mediated hypersensitivity 
reactions. Mast cells and basophils, as well as FcRI bearing APCs, are now known to 
be able to synthesise, store and secrete a variety of cytokines that have important roles 
in the initiation and maintenance of allergic type inflammatory reactions. The 
advances in knowledge of the IgE – FcRI interaction as well as of the cells that 
express FcRI are leading to the development of novel therapeutic agents (such as 
omalizumab). However even when trying to elucidate the mechanisms of more 
conventional therapeutic agents, such as cyclosporin A, or potentially disease 
modifying therapies such as allergen specific immunotherapy, due consideration 
should be given not just to the possible effects of these therapies on FcRI bearing 
cells but also to how the efficacy of the therapy may be enhanced through functional 
manipulation of particular FcRI+ cells (such as dendritic cells). 
The four studies forming the core of this thesis contributed, at least to a small extent, 
to some of these advances in understanding the nature and roles of FcRI bearing 
cells. In the introduction (Chapter 1) I attempted to summarise the diverse studies that 
had taken forward our knowledge of IgE and its high affinity receptor in the first three 
decades after the discovery of IgE and how these related to the studies described in 
these ‘core papers’. In this discussion chapter I have tried to show how the 
observations in these studies have been taken forward, some by researchers in he 
same department where the research for these papers was originally undertaken, but 
many by researchers in other institutions. Whilst research in all these areas still 
continues, this thesis has tried to summarise an exciting epoch in research into a 
fascinating immune receptor.    107
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